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Interest in the formulation of dosage forms to control drug release has 
increased steadily in the last 50 years. In most cases, the purpose is to make a 
product that is able to produce a prolonged therapeutic effect at reduced dosing 
frequency. A large number of substances demonstrate pharmacological effects in
vitro. However, in order to be useful, the active pharmaceutical ingredients (APIs) 
must reach the site of action in a concentration large enough to initiate a 
pharmacological response. APIs are almost never administered to a patient in an 
unformulated state. A dosage form generally consists of one or more APIs, in 
combination with a number of other substances (excipients) that are added to 
facilitate the preparation and administration, to promote the consistent release and 
bioavailability of the API, and to protect the API from degradation. The excipients 
strongly influence the physicochemical characteristics of the final product. The 
successful formulation of a stable and effective dosage form therefore depends on 
the careful selection of excipients. The use of polymers in the formulation of 
controlled drug delivery systems has over the years become an important area of 
research and development. The present trend points to an increasing interest in the 
use of natural ingredients in food, drugs and cosmetics. This is partly attributed to 
greater acceptance by consumers for natural ingredients over synthetic materials 
(Bhardwaj et al., 2000).  
The naturally occurring alginate polymers have been widely used in 
pharmaceutical products due to their unique properties. Alginates were first 
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isolated from seaweeds over a century ago and are now one of the most well 
established hydrocolloids in the market. They cover a wide range of applications 
in the food and industrial sectors as a result of their thickening and gelling 
properties. Alginates contain two different monosaccharide residues, 
-D-mannuronate (M for short) and -L-guluronate (G for short), linked randomly 
by -1,4 and -1,4 glycosidic bonds. Sodium alginate, which is available 
commercially, is used primarily for its ability to form an insoluble gel in contact 
with most divalent cations. The ability to easily form an insoluble matrix has made 
alginate a useful carrier for the entrapment of cells and drugs (Wee and Gombotz, 
1998). However, some limitations are encountered with the use of alginate 
microspheres, such as rapid drug release. Drug release from calcium alginate 
microspheres is generally fast. More than 90% of sulphaguanidine, with aqueous 
solubility of 1:1000 at 25ºC, was released from calcium alginate microspheres 
within 1 hour of dissolution test. This was attributed to the high porosity of the 
alginate matrix and large specific surface area of the microspheres for drug release 
(Wan et al., 1992).    
In recent years, various strategies have been employed to solve the 
problem of rapid drug release. A key consideration in the modification of drug 
delivery systems is the controlled release of drug at the site of action. For example, 
additives such as cellulose derivatives have been employed to modify drug release 
from alginate matrices (Chan and Heng, 1998). In some studies, drug release was 
modified by employing polycations, such as chitosan and poly-L-lysine (PLL) to 
form a polyelectrolyte complex (PEC) with alginate (Chang et al., 1999). However, 
the above studies showed limited success in sustaining drug release from alginate 
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matrices. Therefore, this thesis aims to explore other strategies to develop 
controlled release alginate microspheres. 
The alginate microspheres in this study were prepared by an emulsification 
method using model drugs. The emulsifier and stirring rate were found to play 
important roles in the preparation and characteristics of the products obtained. 
Microspheres of increasing size could be obtained by decreasing stirring rate. 
Hence, the first strategy was to employ particle size to control drug release. 
However, this was met with limited success as drug release was retarded to a small 
extent. 
The second strategy employed a liquid phase coating technique to produce 
polymer-reinforced alginate microspheres. This technique enabled marked 
reduction in drug loss from the microsphere cores to the continuous liquid phase 
during coating. In this study, polymethyl methacrylate and poly (lactic-co-glycolic) 
acid were employed as coating polymers. The microspheres coated with 
polymethyl methacrylate showed markedly lower rate of drug release compared to 
the non-coated ones. The release mechanism and rate were affected by the type of 
polymethyl methacrylate, core:coat ratio and dissolution media used. Coating with 
poly (lactic-co-glycolic) acid was met with limited success. Nevertheless, the 
liquid phase coating technique developed offers an efficient method of coating 
microspheres with markedly reduced drug loss and possible controlled drug 
release. 
It is widely known that poly (lactic-co-glycolic) acid (PLGA) is able to 
sustain drug release for a prolonged period of time and is therefore not suitable 
where relatively fast drug release is desired. On the contrary, drug release from 
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alginate matrix is relatively fast. Hence, the third strategy employed a 
double-emulsion method to combine PLGA with alginate to moderate drug release. 
Discrete and spherical microspheres containing norcantharidin were successfully 
produced. The particle size of the microspheres could be controlled by varying the 
stirring rate employed. Reduction of stirring rate resulted in large microspheres. 
Drug release rate of the microspheres was dependent on the relative proportion of 
PLGA to alginate. Hence, drug release could be controlled by varying the 
proportions of these two components in the matrix. 
The PLGA-alginate microspheres containing norcantharidin were found to 
be promising chemoembolization agents for the treatment of liver cancer. The 
microspheres inhibited the growth of liver cancer cells in in vitro studies. The 
inhibitory effect was dependent on both concentration of microspheres and contact 
time. The microspheres also exhibited embolization of hepatic arteries in rats. In 
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xvi
LIST OF ABBREVIATIONS 
API active pharmaceutical ingredient 
BPAM blank PLGA-alginate microsphere 
BSN bromine-substituted norcantharidin 
DCM dichloromethane 
DDS drug delivery system 
EA ethyl acetate 
GI gastro-intestinal 
HLB hydrophile-lipophile balance 
HPLC high-performance liquid chromatography 
INPAM 125I-labeled BSN-loaded PLGA-alginate microsphere 
NPAM norcantharidin-loaded PLGA-alginate microsphere 
PAMS PLGA-alginate microsphere 
PBS phosphate buffer solution 
PEC polyelectrolyte complex 
PLGA poly (lactic-co-glycolic) acid 
PLL poly-L-lysine
PMMA polymethyl methacrylate 
PVA poly(vinyl alcohol) 
SEM scanning electron microscope 
SGF simulated gastric fluid 
SIF simulated intestinal fluid 




The naturally occurring alginates can be used to formulate 
pharmaceutical products due to their unique properties. A potential application is 
the use of alginate as particulate carriers for active pharmaceutical ingredients 
(APIs). For example, alginate microspheres had been developed as a drug delivery 
system (DDS) for many peptide and protein drugs (Chan and Heng, 1998). An 
ideal DDS is able to control the drug concentration at the target site for a desired 
period of time. In this section, the properties and applications of alginates, 
microparticles and controlled release systems will be discussed. 
A. Alginates 
Alginates are polysaccharides obtained from brown seaweeds. They have 
been widely used in the food and pharmaceutical industries. Traditionally, sodium 
alginate has been used as a tablet binding agent, as well as a tablet disintegrant in 
compressed tablets (Wan and Heng, 1987). Alginates have also been employed in 
the production of capsule shells for medicaments (Narayani and Rao, 1995). These 
afore-mentioned applications generally depended on the thickening, gelling and 
stabilizing properties of alginates. The ability of alginates to form an insoluble 
matrix easily has made them useful carriers for the entrapment of cells and drugs.  
A1 Source and production 
Alginate was first isolated from seaweeds in 1883 by E. C. Stanfort, a 
British pharmacist.
 




species of brown seaweeds, namely Laminaria hyperborea, Ascophyllum nodosum, 
and Macrocystis pyrifera. Other alginate sources include Laminaria japonica, 
Eclonia maxima, Lesonia negrescens and Sargassum species (Smidsrod and 
Skjak-Braek, 1990). The alginates form the major structures of the cell wall of 
brown seaweeds contributing up to 40% of the total dry matter (Sutherland, 1991). 
They are present as mixed salts of sodium, potassium, calcium and magnesium, 
with the exact composition varying with the species of seaweeds (Cook, 1986). 
Interestingly, alginates are also produced by certain bacteria, such as Azetobacter
vinelandii (Sabra et al., 2001). 
The seaweeds grow in abundance on rocky shores. They are harvested 
and washed before drying and milling. Alginates are then extracted by heating the 
milled seaweed in mild alkali to convert the insoluble alginates in the seaweed to a 
soluble form. The alginate extract is filtered and further purified by precipitation 
with acid or calcium salt before it is finally converted to the soluble sodium 
alginate (Sherbrock-Cox et al., 1984).  
A2 Chemical structure and analysis 
Alginates belong to a family of linear unbranched polyelectrolyte 
copolymers comprising -(1,4)-linked D-mannuronate (M) and -(1,4)-linked 
L-guluronate (G) residues. Figure 1 shows the molecular structures of 
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Figure 1   Molecular structures of D-mannuronate and L-guluronate residues and 
their binding to form the alginate polymer (adapted from ref. 23). 
 
Alginates may be prepared in a wide range of average molecular weights 
(50 to 100 000 residues). The residues have been found to be arranged in three 






blocks (-G-G-G-) and mixed blocks (-M-G-M-G-). The number and length of the 
blocks determine the physical properties of the alginates (Kennedy and White, 
1988). 
High-field 1H and 13C NMR spectroscopy was employed for 
characterizing alginate (Johnson et al., 1997).  Using this technique, the 
monomer compositions, as well as the frequencies of the four possible diad 
structures (FGG, FMG, FMM and FGM) were determined. Circular dichroism 
spectroscopy was also used to match the linear spectra of the alginate to model 
samples of well-characterized homopolymeric blocks (Krishna and Sharma, 1991; 
Donati et al., 2003).  
 
Figure 2   Different types of alginate conformations: (a) poly--(1,4)-linked 
D-mannuronate segment; (b) poly--(1,4)-linked L-guluronate 
segment; and (c) alternating poly--(1,4)-linked L-guluronate- 
-(1,4)-linked D-mannuronate segment (adapted from ref. 23).  
 
INTRODUCTION
The crystalline structures of polymannuronate and polyguluronate 
segments were studied by X-ray diffraction and polarized infrared spectroscopy 
(Sherbrock-Cox et al., 1984; Anastassiadou et al., 1996). The polymannuronate 
segment was found to exist as a flat ribbon-like structure (Figure 2a), while the 
polyguluronate segment was buckled and ribbon-like (Figure 2b). The ribbon-like 
conformation is stabilized by intramolecular hydrogen bond between the hydroxyl 
group and the oxygen atom of the carboxyl group of adjacent units. Alternating 
poly -(1,4)-linked L-guluronate--(1,4)-linked D-mannuronate contains both 
equatorial-axial and axial-equatorial links that result in a disorderly conformation. 
In this conformation, hydrogen bonds are formed between the carboxyl group of 
the mannuronate and the hydroxyl groups in the 2- and the 3-positions of the 
adjacent guluronate. Chaplin found that the overall flexibility of the mixed 
segment was greater than that of the poly -(1,4)-linked D-mannuronate segment 
due to differences in the degree of freedom of the two residues (Figure 2c). 
The amount of each component (M and G) depend on the species of 
seaweed, the condition of growth and the part of the seaweeds (stalk or leaf) from 
which the alginate is derived. Table 1 lists the various sources of alginates and 
their compositions. It was reported that the content of L-guluronate increased as 











A3 Properties  
A3.1 Physical properties 
Alginic acid is insoluble in water but swells on contact with an aqueous 
medium. The water-soluble form of alginate is made by neutralizing alginic acid 
with sodium or potassium salts. The water-insoluble forms include alginate salts of 
multivalent ions such as calcium, lead and chromium. 
The flexibility of the alginate polymers in solution increases in the 
following order: MG>MM>GG. Alginate gels with the lowest shrinkage, highest 
porosity, and best stability towards monovalent cations are made from alginates 
with a guluronate content greater than 70% and an average length of 
polyguluronate block greater than 15. The gels made from these "high G" 
alginates are rigid and brittle (Wandrey et al., 2003; Draget et al., 2003).  
Alginates dissolve in both hot and cold water to give solutions with a 
wide range of unusually high apparent viscosities, even at 1% solute concentration 
for some grades, due to their high molecular weight and rigid structure (Kennedy 
and White, 1988). The viscosity of alginate solution increases logarithmically with 
its concentration (Gan and Lin, 1997).  Addition of water-miscible solvents, such 
as alcohols, glycols or acetone, increases the viscosity of the alginate solution and 
upon reaching a certain concentration, the alginate will precipitate. The various 
alkaline solutions of alginate are tasteless and almost colourless. Alginates are 
very useful especially in food products because they are natural polymers of plant 
and not animal origin and are readily available. They are non-calorific and safe for 
consumption. 
INTRODUCTION
A3.2 Chemical properties 
One of the most important properties of alginates is their ability to form 
gels by reaction with divalent or polyvalent cations, such as Ca2+, Ba2+, Zn2+ and 
Al3+. In principle, any multivalent cation can cause gelation of alginate except for 
Mg2+. The affinity of various cations for the alginate polymer was found to 
decrease in the following order: Pb2+ > Cu2+ > Cd2+ > Ba2+ > Sr2+ > Ca2+ > Co2+, 
Ni2+, Zn2+ > Mn2+ (Haug and Smidsord, 1967). Among these ions, Ca2+ is 
commonly used to cross-link sodium alginate. Other divalent cations such as Pb2+, 
Cu2+, Cd2+, Co2+, Ni2+ and Mn2+ have limited use due to their toxicity (Smidsord 
and Haug, 1972).  
Alginate gels are formed by crosslinking of the polymer chains. This 
mainly results from specific and strong interactions between divalent or polyvalent 
cations and blocks of guluronate, but not mannuronate residues. Therefore, the gel 
strength in alginate is related to the level of L-guluronate present. Calcium ions 
have been reported to bind preferentially to the L-guluronate residues in a planar 
two-dimensional manner, producing the so-called "egg-box" structure, with the 
cooperative unit comprising more than 20 monomers (Figure 3). 
The “egg-box” is proposed to contain 10 oxygen atoms from the 
guluronate chains involved in the coordination of the calcium ions. Six oxygen 
atoms can interact directly with the calcium ion present in the box. The other four 
oxygen atoms are from the (1,4)-O linkage and the ring of each chain. The chains 
are stabilized by hydrogen bonding between the other carboxylate oxygen and two 






Figure 3  The “egg box model” for the interaction between Ca2+ and 
poly-guluronate. Dark circles represent the oxygen atoms involved in 
the coordination of calcium ion (adapted from ref. 67).  
 
Although alginate gels are mainly composed of water, they are able to 
resist stress and retain their shape. Several investigators observed that positively 
charged drugs can potentially compete with calcium ions for the binding sites on 
the alginate polymer although the microenvironment in an alginate gel can be 
relatively inert to these drugs (Stockwell et al., 1996 and Rajaonarivony et al., 
1993). Alginates also form strong complexes with polycations such as chitosan, 
polyethyleneimine (Haumont et al., 1991) or polyacrylamide (Prabhune and 
Sivaraman, 1991). These complexes are not affected by Ca2+ chelators and can be 




A3.3 Biological properties 
The biocompatibility of alginates has been studied by various 
investigators. Alginates are included in a group of compounds that are generally 
regarded as safe (GRAS) by the Food and Drug Administration of the United 
States of America (Orive et al., 2002). Nevertheless, some studies have reported 
side-effects of alginates in pharmaceutical applications. Some investigators have 
reported that mannuronic acid is the major initiator of the foreign body reaction 
(Klock et al., 1997; Orive et al., 2005). It is therefore strongly recommended by 
these investigators that alginates with low mannuronic acid and high guluronic 
acid contents should be employed if inflammatory reactions are to be avoided. 
However, some other investigators have found guluronic acid to be responsible for 
the fibrotic overgrowth (Zimmermann et al., 1992). There have been several 
efforts to solve this problem. It should be pointed out that alginates are available in 
several different grades of purity. One study showed that mitogenic impurities, 
which are found in the commercial grade of alginates but not in the pure grade, are 
solely responsible for the side-effects observed. It was noted that the studies that 
reported side-effects were performed with crude alginates which are known to 
contain contaminants that can provoke an inflammatory reaction. Purification of 
alginates, which involves a number of filtration, precipitation and extraction steps, 
is therefore necessary to improve their biocompatibility. Ultra-pure grade of 
alginates may be used as implants in combination with drugs (Tonnesen and 
Karlsen, 2002). 
Besides biocompatibility, alginates possess bioadhesive property that 




their carboxyl end groups, are classified as an anionic mucoadhesive polymer. 
Chickering et al. (1992, 1995) conducted some studies to evaluate the adhesive 
forces between different polymers and intestinal mucosa. Their results showed that 
alginate has the highest mucoadhesive strength when compared to polymers such 
as polystyrene, chitosan, carboxymethylcellulose and poly (lactic acid). The same 
conclusion was made in another study by Park and Robinson (1984), in which 
polyanionic polymers were found to be more effective bioadhesives than 
polycationic or nonionic polymers.  
A3.4 Stability and degradation 
Alginates have been reported to undergo proton catalyzed hydrolysis 
which is dependent on time, pH and temperature (Haug and Larsen, 1963). 
Degradation of a Ca2+-crosslinked alginate gel can occur through displacement of 
the Ca2+ by a high concentration of monovalent cations such as Na+. This 
ion-exchange decreases the extent of crosslinking between the polymer chains. It 
can lead to leakage of entrapped material and dissolution of the alginate polymer 
(Sutherland, 1991). In ultra-pure water where electrolyte content is very low, 
erosion of Ca2+-crosslinked alginate matrix is insignificant because there is little 
displacement of Ca2+ by ion exchange (Vandenbossche and Remon, 1993). 
Calcium alginate beads remain intact at low pH. They swell and 
disintegrate in 0.1 M phosphate buffer and completely dissolve in 0.1 M sodium 
citrate at pH 7.8 (Kwok et al., 1991). The swelling and disintegration of calcium 
alginate beads are therefore dependent on the composition of the dissolution 
medium. In intestinal fluids, sequestration of the crosslinking calcium ions can 





Alginates have been used extensively in food products and cosmetics 
(Wee and Gombotz, 1998). For example, they are used to improve pouring and 
handling properties of liquid detergents and shampoos, as well as to retard phase 
separation and ice crystal growth in ice-cream. In the pharmaceutical industry, 
sodium alginate has been used as a tablet binding agent, as well as a tablet 
disintegrant in compressed tablets (Wan and Heng, 1987). Alginates have also 
been employed to prepare gel capsules, to modulate viscosity of liquid 
preparations and to produce semi-solid products with good spreading properties 
(Narayani and Rao, 1995). These applications generally depend on the thickening, 
gel-forming and stabilizing properties of alginate.  
The ability to easily form an insoluble matrix has made alginate a useful 
carrier for the entrapment of drugs. Alginate carriers are commonly formulated as 
particles, such as beads and microspheres. Drug release from the particles can be 
regulated by controlling the properties of the alginate matrix through the use of 
different types and concentrations of alginate and crosslinking ion. Alginate beads 
are easily prepared by extruding sodium alginate solution into an aqueous solution 
of multivalent cations. This process can be carried out under an extremely mild 
environment, using non-toxic reactants. For this reason, alginates have been 
extensively studied for the delivery of proteins and other active pharmaceutical 
ingredients (APIs). Examples include melatonin (Lee et al., 1998), heparin 
(Chinen et al., 2003), bovine serum albumin (Witschi and Misny, 1999), nerve 
growth factor (Maysinger et al., 1994), vaccines (Borges et al., 2005), diclofenac 




1994), vancomycin (Ueng et al., 2000 and 2004) and theophylline (Bodmeier and 
Wang, 1993; Miyazaki et al., 2000). 
Due to mildness of the encapsulation method, alginate has become the 
polymer of choice for cell encapsulation. Alginate-poly-L-lysine encapsulation 
system was successfully applied to pancreatic islets for transplantation in rats 
(Garfinkel et al., 1998). Several other different cell lines had been encapsulated in 
alginate gel systems for a wide range of therapeutic applications, including rat 
hepatocytes (Sun et al., 1987), hybridoma cells (Miyamoto, 1999) and baby 
hamster kidney cells (Joki et al., 2001). 
An emulsification method developed for microencapsulation of living 
cells was employed in the production of vaccines such as Bacillus 
Calmette-Guerin (BCG). The microspheres were formed by internal gelation of an 
alginate solution emulsified in vegetable oil (Esquisabel et al., 2000). A conjugate 
of polysaccharide antigen (PS19) and cholera toxin B subunit (CTB) was also 
encapsulated in alginate microspheres (Cho et al., 1998). These microspheres, 
produced by a diffusion-controlled interfacial gelation technique, showed a 
sustained release profile, with 80% antigen released over one day. Peroral 
vaccination with 25 mg of PS19-CTB-alginate microspheres was found to evoke 
mucosal IgA and systemic IgM responses to PS19.  
Alginate microspheres possess a number of advantages. They can be 
prepared without using heat and organic solvent. The microspheres have a 
relatively inert aqueous environment within the matrix. In addition, the matrix has 




this can be modified by coating the matrix. Lastly, but not the least, the 
microspheres can be degraded under normal physiological conditions. 
B. Microspheres, microcapsules and microparticles 
Microspheres and microcapsules are collectively referred to as 
microparticles. Microspheres are monolithic and may contain dispersed drug in 
liquid or solid form, whereas microcapsules consist of drug concentrated in a 
central core inside a polymer-rich wall or shell (Willmott and Daly, 1993). Figure 
4 illustrates the various configurations of these microparticles. Strictly speaking, 
the size of microparticles ranges between 1 and 1000 m (Mathiowitz, 1999). 
However, in practice, particles with size ranging from about 0.2 to 2000 m have 
been referred to as microparticles.  
       
(a) 
      
(b) 
Figure 4   Various configurations of (a) microcapsules and (b) microspheres 
(adapted from ref. 88). 
 
Microparticles, which can be formed by a variety of microencapsulation 
techniques, offer several advantages in their use as drug delivery systems: (a) their 
formulation may be optimized to produce high drug load, (b) the kinetics of their 




and (c) the surface of the microparticles can be modified by attaching ligands, 
such as antibodies, which would enable them to target specific organs and sites in 
the body (Brown and Dennis, 2003).  
Microencapsulation has a long history of application in the food, 
consumer products and cosmetics industries. Flavors have been encapsulated since 
the 1930s, vitamins since the 1940s and ink for carbonless paper since 1956 
(Brannon-Peppas, 1993). The concept of using semipermeable microcapsules for 
the delivery of therapeutic biological agents was pioneered by T. M. Chang almost 
40 years ago (Chang, 1964) and over the years, a wide range of drugs such as 
steroids, vitamins and antibiotics had been encapsulated. Both natural and 
synthetic polymers have found wide applications in the field of microencapsultion.  
B1 Techniques of microencapsulation 
Microparticles can be formed by a variety of microencapsulation 
techniques. A number of factors have to be considered when selecting a suitable 
microencapsulation technique. These factors include the characteristics of the 
operation, the properties of the drug and the polymers used and the final 
configuration of the product. Among these techniques, coacervation, solvent 
evaporation, spray drying and extrusion are widely used. 
B1.1 Coacervation 
Coacervation describes the phase separation of a polymer-rich liquid 
from a solution when the solubility of the polymeric component is reduced by 
some chemical or physical means, such as addition of electrolyte or solvent and 




is removed from the coating material by an agent with a greater affinity for water. 
The dehydrated molecules of coating material would aggregate around the core 
material to form the coacervate. Ethanol is commonly used as an agent to induce 
coacervation. In fact, any organic liquid that is miscible with water and is a poor 
solvent for the coating material can be employed. Coacervation of the coating 
material can also be induced by addition of salts, especially those containing 
cations with a high affinity for water, such as sodium. Coacervation of ionic 
polymers, such as gelatin, is accomplished mainly by charge neutralization of the 
polymer rather than by dehydration (Thies, 1982).  
B1.2 Emulsion-solvent evaporation 
The solvent evaporation method is one of the oldest and most widely 
used methods of microsphere preparation. In this method, the polymer is dissolved 
in a suitable solvent, and the active ingredient is dispersed or dissolved in this 
polymer solution. The resultant mixture is then dispersed in a continuous phase to 
form discrete droplets. Microspheres form and harden as the solvent evaporates 
from the droplets. Free flowing microspheres can be obtained after suitable 
filtration and drying.  
Although the solvent evaporation method is conceptually simple, many 
variables can influence the final product. The speed of solvent evaporation has 
been found to affect the size, as well as drug content, of the microspheres 
produced. All the microspheres formed by this method possess rough surfaces, 
with depth of pores varying according to the viscoelastic properties of the polymer 




The solvent plays an important role in the formation of microspheres and 
affect particle size and other physicochemical properties. The solvent used should 
possess the following properties: (a) readily dissolves the polymer, (b) immiscible 
or only slightly miscible with the continuous phase so that an emulsion can be 
formed, and (c) a low boiling point so that the solvent molecules leaching from the 
polymeric dispersed phase to the continuous phase can evaporate readily to the air 
(Sah, 2000). 
B1.3 Spray drying and spray congealing  
Spray-encapsulation is also one of the most widely used 
microencapsulation method and was first employed in the 1930s to prepare 
microencapsulated flavors with gum acacia. The first step in spray drying is to 
disperse the core material in a solution of coating substrate. The resultant mixture 
is then sprayed through a fine atomizing nozzle into an evaporation chamber with 
hot drying air to produce microencapsulated particles (Takada et al., 1995). The 
particle size typically falls between 10 and 300 m in diameter. Spray drying is 
advantageous as it is a well-established technology and the equipment is capable 
of high product throughput. Heat-sensitive core substances can be coated by this 
method because the time of exposure to elevated temperature is extremely short. 
Moisture-sensitive materials can also be encapsulated by the use of nonaqueous 
coating systems (Gibbs et al., 1999). 
The loss of volatile core contents during the “drying” stage of spray 
drying producing porous particles have led to a number of alternative methods for 
dehydration (desolvation) of sprayed microdroplets. These methods include spray 




Fanger, 1971). The spray congealing process is similar to spray drying except that 
no solvent is used with the coating material. The coating material is meltable at an 
elevated temperature. The molten liquid or suspension is atomized and congeals 
into droplets upon meeting the cool air in the spray congealer. Congealing can also 
be accomplished by spraying the dispersion of core material in the coating solution 
into a chilled organic solvent, desolvating liquid or sorptive particles (Passerini et
al., 2003). Both the spray drying and spray congealing processes have the 
advantage of being rapid single-stage operations suitable for batch or continuous 
production of large quantities of product. 
B1.4 Droplet extrusion and centrifugal extrusion 
In the droplet extrusion method, the polymer in the form of liquid, melt, 
or solution is ejected from the orifice of a fine tube or nozzle to form 
microdroplets. The droplet size is dependent on the diameter of the tube or nozzle 
and the ejecting velocity, which is regulated by a vibrator. There are two methods 
of coating the core material. The coating material can be premixed with the core 
material to form the droplets. Alternatively, the coating of the particle is formed as 
the droplet of core material passes through the medium of coating material. The 
thickness of the deposited coat can be varied. This method has been reported to 
produce microcapsules of identical size (Madan et al., 1976; Matsumoto et al., 
1986). Droplet extrusion using commercial equipment normally produces large 
microcapsules of 200 to 500 m (Donbrow, 1992). 
In centrifugal extrusion, two immiscible liquids consisting of the core 
and coating materials respectively are pumped through a spinning two-fluid nozzle. 




spontaneously break up into a stream of spherical droplets upon emerging from the 
nozzle. Each droplet contains a core surrounded by a continuous liquid coat. If the 
coating material is a relatively low-viscosity hot melt that solidifies rapidly on 
cooling, the droplets are converted into solid particles as they fall away from the 
nozzle. Alternatively, droplets emerging from the nozzle may be coated by a 
solution of polymer with the ability to congeal rapidly by chemical reaction. These 
droplets fall into a gelling bath where the coats solidify, resulting in the production 
of microspheres. Particles produced by this method have diameters ranging from 
150 to 2000 m (Gibbs et al., 1999). 
B2 Use of particulate systems in cancer therapy 
With the vast array of encapsulation techniques currently available, most 
active agents can be incorporated into a microparticulate formulation. Particulate 
formulations are potentially useful in the treatment of diseases that respond well to 
controlled drug delivery (Ravi Kumar, 2000). Among these diseases, cancer is 
well-known to seriously threaten human health and it is a leading cause of death. 
A general review of the use of particulate systems in cancer therapy is presented in 
the following section. 
B2.1 Oral drug delivery 
Much published work on microspheres has been directed at their use as 
targeting and delivery systems. Research on the oral administration of particulates 
has been concerned mainly with their sustained-release potential to achieve both 
reduced local dissolved drug concentration in the gut and prolonged drug level in 




through intestinal membranes, the oral route poses both new opportunities and 
new challenges.  
For commercial use, microspheres are formulated into pharmaceutically 
acceptable oral delivery systems, such as tablets, capsules and dry powder for 
reconstitution into a suspension. Anticancer agents are typically hydrophobic and 
unstable in water, making formulation development a challenge. The delivery 
system ultimately developed should be able to consistently control the time course 
and extent of drug absorption. The ability to scale up its production is also an 
important consideration. There is increasing interest to gain a better understanding 
of mechanisms, efficiency and reproducibility of translocation of carrier and/or 
drug across the gastro-intestinal tract, as well as analysis of the effect of carrier 
composition on these parameters (Robinson and Mauger, 1991; Andrianov and 
Payne, 1998).  
B2.2 Implantable drug delivery 
In the last few decades, microspheres based on lactide/glycolide 
polymers have steadily gained importance in the field of drug delivery. These 
small particles are preferred to large implants that entail more invasive and painful 
administration. They have also become one of the most popular injectable 
controlled-release dosage forms. Preparations of gonadorelin agonists, such as 
lutenizing hormone-releasing hormone are commercially available. This hormone 
is formulated as lyophilized microspheres that are resuspended in a diluent for 
intramuscular injections every 1, 3 or 4 months. This approach to drug delivery is 
very appealing for a number of classes of drugs, particularly those which cannot 




gonadorelin, serum testosterone level was suppressed to castrate level within 30 
days for 95% of the patients (Saltzman and Fung, 1997).  
Despite extensive study on the formulation of microsphere preparations, 
they still remain a complicated dosage form to prepare, bearing many difficulties 
and problems. For example, microspheres often fail to yield the desired 
drug-release behavior for sensitive drugs, such as proteins and peptides because of 
poor drug-release control or stability problems (Kang et al., 2002). Many 
problems with microspheres are a direct result of their microstructure and their 
physical changes due to erosion. Additional problems can arise from complicated 
drug-polymer interactions. 
B2.3 Chemoembolization 
Chemoembolization involves the selective arterial embolization of a 
tumor, accompanied by simultaneous or subsequent local delivery of 
chemotherapeutic agents. The advantage of this mode of treatment lies in the 
synergistic effect produced by embolization and local chemotherapy. The 
chemoembolization of tumors relies on two basic principles: (a) the embolization 
of vessels that feed the tumor and (b) the kinetics of drug release from the emboli. 
Microspheres can exert a twofold action since they are not only embolization 
agents but also drug carriers (Harris et al., 2001). 
Despite the potential benefit of chemoembolization, its application is 
limited by the following factors, (a) the mode of treatment involves a sophisticated 
procedure that has to be carried out in specialized medical units, (b) the number of 




necessarily a direct dependence between drug level and rate of response (Harris et
al., 2001; Ramsey and Geschwind, 2002). 
Nevertheless, the use of microsphere-based therapy allows drug release 
to be carefully tailored to the specific treatment site through formulation. The total 
dose of medication and the kinetics of release are variables, which can be 
manipulated to achieve the desired therapeutic outcome. Being small in size, 
microspheres have large surface to volume ratios and can be used to control the 
release of insoluble drugs.  
C. Controlled release system 
The manner in which a drug is delivered to the target site is almost as 
important as the drug itself. In the past few decades, considerable advances have 
been made in the development of controlled drug delivery systems (Szycher, 
1986). This is partly due to the drawback of conventional drug delivery systems 
such as injections, capsules and tablets, which necessitates frequent dose 
administration to maintain the drug concentration in the body within the 
therapeutic window. In addition, the administration of injections usually incurs 
pain. Drug delivery systems that are able to maintain the desired plasma drug 
concentration for a prolonged period are certainly desirable as they will improve 
patient compliance and eliminate the possible side effects caused by fluctuations 
in blood levels as well as high frequency of drug administration.  
C1 Concepts of controlled release 
Controlled drug delivery is an attempt to control the drug availability at 




delivery of drug. In time-controlled delivery, the drug is released in a 
pre-determined rate while in target-controlled delivery, the drug is delivered to a 
specific site. The delivery system may be administered by the intravenous, 
transdermal, pulmonary or oral route.  
The drug release kinetics, which is dependent on the type of delivery 
system, determines the profile of the drug concentration in the plasma (Figure 5). 
In time-controlled delivery, the aim is to maintain the plasma concentration within 
the therapeutic range for a longer period of time. This can be achieved by 
encapsulating the drug in a carrier, such as microspheres. After the microspheres 
are administrated into the body, the drug is leached out gradually. With careful 
design and fabrication, drug concentration can be maintained within the 
therapeutic range for weeks, months, and even several years (Banker and Rhodes, 
2002).  
 
Figure 5  Drug concentration profile after the drug is delivered at different 




Drugs may be incorporated into various drug delivery systems (DDS) 
with different mechanisms of release. Examples of DDS include polymer matrix 
(Brannon-Peppas, 1993), liposomes (Stenekes et al., 2000), micelles (Kim et al., 
2000; Chi et al., 2003), emulsions (Clement et al., 2000) and microchips (Santini, 
Jr. et al., 1999). Among all the above-mentioned DDS, polymer matrices are the 
most investigated. They possess obvious advantages over conventional delivery 
systems by (a) protection of drugs from degradation and metabolism in the 
physiological environment, (b) sustained release of drug to maintain concentration 
within therapeutic range for a longer period of time, (c) elimination of side effects 
due to fluctuating drug levels, and (d) reduced frequency of administration. These 
advantages will ultimately result in better therapeutic outcome and patient 
compliance. Such delivery systems are preferable for drugs which have high 
systemic toxicity and high administration frequency. Typical examples include 
drugs for chemotherapy and proteins for certain deficiency (Bauer, 1999; Kumar 
and Kumar, 2001).  
It should be noted that controlled release polymeric delivery systems 
have several drawbacks (a) the polymer may not be totally biocompatible and 
non-toxic, (b) administration will involve a surgical procedure if the delivery 
system is a large implant, (c) the polymer may be expensive, and (d) it is difficult 
to shut off the release after the delivery system is applied to the body (Langer and 
Peppas, 1981). 
C2 Polymers used in controlled release delivery systems 
The application of polymers in the formulation of controlled release DDS 




(Bruck, 1982). There are many types of polymers, with varying chemical and 
physical properties, available commercially. There is no ideal polymer as each has 
its merits and limitations. A good knowledge of polymer is useful for the selection 
of the most suitable polymer in the formulation of a delivery system. 
C2.1 Classification 
Both non-biodegradable and biodegradable polymers are widely used in 
the formulation of controlled release DDS. The main advantage of using 
biodegradable polymers is that a second surgery to remove the implanted DDS is 
not required as the polymer is totally absorbable in the human body (Heller, 1984). 
On the other hand, bio-compatible but non-degradable polymers have the 
advantage of availability, inertness and physical strength. Silicone rubber and 
ethylene vinyl acetate (EVA) are typical examples of non-biodegradable polymers. 
Silicone rubber was used to entrap small molecule drugs about 40 years ago 
(Sarkar, 2003). EVA has been successfully used to deliver contraceptive hormones 
and lipophilic drugs (Le and Tsourounis, 2001). Polyurethane, another 
non-biodegradable polymer, is useful as a carrier for peptide and protein drugs 
(Zdrahala and Zdrahala, 1999). Since a second operation is needed to remove 
non-degradable implants after the drugs are depleted, biodegradable polymers are 
preferred in the formulation of such DDS. 
Bio-compatible polymers may also be classified as natural or synthetic. 
Both classes of polymers are widely used in the formulation of drug carriers. 
Natural polymers, such as bovine serum albumin (BSA) (Bozdag et al., 2001), 
collagen (Wang et al., 2003), gelatin (Cascone et al., 2002; Ulubayram et al., 2002) 




drug release. The main advantage of natural polymers over synthetic materials is 
their better biocompatibility due to their natural origin. On the other hand, their 
composition may vary from batch to batch as they are derived from animal or 
plant sources. Moreover, the tedious process as involved in purifying and 
standardizing make these natural polymers more expensive (Hanker and 
Giammara, 1988). In contrast, synthetic polymers are more easily purified and 
standardized and can be produced economically in large quantities. These 
advantages make synthetic polymers attractive and preferred choices for the 
formulation of controlled release DDS especially if they are for the oral route. 
Poly(anhydrides), poly(amino acids), poly(esters), poly(orthoesters), 
poly(urethanes), poly(acrylamides), poly(phosphoesters) and poly(phosphazenes) 
are typical examples of synthetic polymers that are widely used in the formulation 
of controlled release DDS (Behravesh et al., 1999). The use of synthetic polymers 
that are biodegradable had increased over the past two decades. Among these, the 
aliphatic poly(esters), such as poly(lactide) (PLA), poly(glycolide) (PGA) and  
the co-polymer poly(lactide-co-glycolide) (PLGA), are the most popular because 
of their excellent biocompatibility, biodegradability and commercial availability. 
Their use in the formulation of controlled release DDS had been approved by the 
Food and Drug Administration (FDA) of USA. In addition, the duration of 
degradation of PLGA can be modified from days to years by changing the ratio of 
lactide and glycolide in the polymer. Therefore, this aliphatic polyester was 





Polymethacrylates are fully synthetic. One of the advantages of these 
group of polymers is their stability to the pH conditions of the digestive tract. 
Polymethacrylates for pharmaceutical purposes are commercially known as 
Eudragit (Lehmann, 1988). Besides its crystal clarity, polymethyl methacrylate has 
high break resistance, light weight and substantial hardness. It also has an 
exceptional decade-long stability to air, light and water, which provides a good 
basis for its use as a coating polymer to prolong the shelf-life of the coated dosage 
forms. These favorable properties are attributed to the structure of the polymer 
skeleton, which is composed of a continuous carbon chain acting as the backbone, 
and methyl side groups that contribute a high degree of rigidity (Petereit et al., 
1995). It is these methyl side groups which make polymethacrylates so much 
stiffer than the other soft and sticky polyacrylates.  
The ester groups in the side chains of polymethacrylates are extremely 
resistant to hydrolysis. Even in alkaline medium, only the individually exposed 
terminal groups are prone to saponification. The degree of hydrolysis is thus 
scarcely measurable and acrylic polymers can, for this reason, also be used for 








Type of polymethacrylates R Properties 
Methacrylic acid copolymers a 
EUDRAGIT® L 100-55/L 100/S 100 
-COOH gastroresistant 
enterosoluble 
Aminoalkyl methacrylate copolymers b 
EUDRAGIT® E 100 
-COOCH2CH2N(CH3)2 gastrosoluble 
permeable 
Ammoni methacrylate copolymers b 
EUDRAGIT® RL 100/RS 100 
-COOCH2CH2N+(CH3)3Cl- permeable 
Methacrylic ester copolymers a 
EUDRAGIT® NE 30 D 
-COOCH3 pH-independent 
a = polymerization in emulsion 
b = polymerization in bulk 
Figure 6  Chemical structure of acrylic polymers (adapted from ref. 80). 
 
Before polymethyl methacrylate was used for pharmaceutical coating 
applications, it was used in the manufacturing of artificial joints and implants as 
the material was easily machined and thermoformed. Compatibility with the skin 
and mucous membranes enabled it to be used in the development of artificial teeth, 
contact lenses and intraocular lenses. In the course of time, the pure 
polymethacrylate was modified by copolymerization with acrylic esters and other 
monomers to suit special needs, especially as far as hardness and porosity were 




Neutral polymethacrylates are pharmacologically inactive. Good 
compatibility with the skin and mucous membranes prompted their use for wound 
sprays and ointment bases (Wong et al., 1999; Gupta and Jain, 2004). Crosslinked 
copolymers based on methacrylic acid serve as ion exchangers for absorption of 
active ingredients in the manufacture of sustained-release formulations in the form 
of tablets and suspensions.  
For sustained release, active ingredients can also be embedded in 
water-insoluble polymers, e.g. by tablet compression together with polymer 
powders or by extrusion at the softening temperatures of the polymers between 
120 and 200 °C (Young et al., 2003). Probably the most important role of 
polymethacrylates in pharmaceutical manufacturing is to be coating polymers for 
coating oral dosage forms to control the release of the active ingredient. 
There are mainly three types of Eudragit depending on the monomers. 
The cationic polymer Eudragit E carries amino groups. Its films are, therefore, 
insoluble in the neutral medium of saliva, but dissolve by salt formation in the acid 
environment of gastric fluid. Anionic acrylic polymers such as Eudragit L and S 
carry carboxyl groups. They are insoluble in acid medium, i.e. resistant to gastric 
fluid, and dissolve only in the neutral to weakly alkaline medium of the small 
intestine. By contrast, permeable acrylic polymers such as Eudragit RL and RS are 
water-insoluble over the entire pH range, but swell in digestive fluids 




C2.3 Poly(lactide) and poly(lactide-co-glycolide)  
These polymers were initially developed to be used as suture materials 
(Shive and Anderson, 1997). Poly(lactide) (PLA) can exist in the form of 
poly(L-lactide) (PLLA), poly(D-lactide) (PDLA) and poly(D,L-lactide) (PDLLA) 
due to the optical activity of lactic acid (Figure 7). The homopolymers or 
copolymers are obtained by the ring opening reaction and condensation 
polymerization of cyclic diesters of lactide or glycolide. PLA is soluble in 
common organic solvents, such as methyl chloride, ethyl acetate and 
tetrahydrofuran. PLA is more hydrophobic than poly(glycolide) (PGA) because of 
the presence of methyl group. In contrast, PGA has a very high crystalinity 
(45-55%) and is almost insoluble in most common solvents (Deasy et al., 1989). 
Generally, PGA is seldom used alone as the polymeric material to formulate the 
controlled release DDS. The PLA and copolymer PLGA are usually used for their 
versatility in modifying physical properties, good predictability of in vitro and in
vivo degradation properties and flexibility of formulation. 
 
Figure 7  Diastereoisomeric forms of lactide (adapted from ref. 88). 
 
PLLA is a semicrystalline polymer because of the high regularity of its 




irregular structure of the polymer chain. The crystalline and hydrophobicity of 
PLLA make it very difficult for water to penetrate into the solid phase of the 
polymer. Since the lactide/glycolide polymers are degraded by hydrolysis of their 
backbone to monomeric acids, the bio-degradation of PLLA is very slow. It was 
found that it took two years for such a polymer to be totally absorbed in the human 
body (Amecke et al., 1992). PDLLA can degrade at a faster rate because the solid 
phase can absorb water due to its amorphous property that results from the random 
distribution of lactic and glycolic monomers in the polymer backbone. Therefore, 
PDLLA is more frequently used in the design of DDS (Jain et al., 1998). 
 
Figure 8  Chemical structure of PLGA and its monomers. 
 
PLGA is most often used to compared with PLLA or PDLLA. Their 
different physical and chemical properties may be due to differences in their 
composition (lactic/glycolic ratio) and molecular weight. With the higher ratio of 
lactic/glycolic acid, there are more lactic acid monomers in the polymer chain. 
Since lactic acid is more hydrophobic than glycolic acid, the polymer with a 
higher lactic/glycolic ratio degrades more slowly. PLGA 50:50 was found to 




took about 150 days, while PDLLA was completely degraded in 12-14 months in 
phosphate buffer solution (Jeffery et al., 1993). 
The degradation of lactic/glycolic polymers follows the homogeneous 
bulk erosion pattern. The polymer chain is first broken down into smaller 
segments by hydrolysis. The polymeric DDS can maintain their structural integrity 
until the polymer segments become water-soluble when they reach a critical 
molecular weight value. The segments are further hydrolyzed into monomeric 
acids and eventually eliminated from the body through the Krebs cycle (Shive and 
Anderson, 1997). The process of mass loss is termed as erosion. For the high 
molecular weight drugs, such as proteins, which cannot diffuse through the 
polymeric network mesh among the polymer chains, erosion has a large 
contribution to the release behavior since it may change the porosity of the bulk 
polymer solid phase. A three-phase in vitro degradation mechanism was proposed 
(Iwata et al., 1999). First, random hydrolytic chain scissions of swollen polymer 
occur. Subsequently, the molecular weight of the polymer decreases significantly, 
but no appreciable weight loss and soluble monomer products can be detected. 
Degradation is next followed by a further decrease in molecular weight, 
accompanied by a rapid loss of mass with soluble oligomer and monomer products 
being formed. The soluble monomer products are further cleaved to form smaller 
molecules in the aqueous medium. 
The process of degradation is self-catalyzed by the presence of acidic 
by-products (Wu and Wang, 2001). Therefore, the degradation of these polymers 
is affected not only by the lactic/glycolic ratio and molecular weight, but also by 




et al., 1994; Park, 1995). Such factors affect the degradation process through 
changing the build-up of the acid in the degrading polymer phase. For example, 
microspheres of larger sizes degrade at a slower rate because the acidic 
by-products cannot diffuse efficiently out of the polymer matrix within a short 
time (Park, 1995). 
C3 Drug release mechanisms of controlled release delivery system  
Drug release mechanisms depend on the properties of the polymeric 
carrier, drug and additives present. The release of drug from polymeric DDS can 
be diffusion-controlled, dissolution-controlled, swelling-controlled or any 
combination of these mechanisms. 
C3.1 Diffusion-controlled system 
In this system, the drug release profile is controlled mainly by diffusion 
according to Fick’s law (Chien et al., 1979). The drug can be embedded into a 
polymer solid matrix or a reservoir. The former configuration includes 
nanospheres, microspheres, macrospheres, slabs, rods and films, where the drug is 
distributed in the polymer solid phase. A homogeneous drug distribution is 
preferable, but this is very difficult to achieve in most cases. The reservoir type 
devices consist of the drug surrounded by a polymer barrier that controls the rate 
of diffusion. The polymers used in diffusion-controlled devices are generally inert 
and biocompatible, such as ethylene vinyl acetate (EVA), silicone rubber and 





The reservoir type DDS can be designed to release small molecule drug 
with near zero-order release profile by maintaining the level of encapsulated drug 
above its solubility. Zero-order release means that the drug is released at a 
constant rate over a period of time. In contrast, the drug release rate from the solid 
matrix usually decreases with time. The drug from the surface or outer layer of the 
polymer matrix diffuses out first and a fast release rate is observed. The drug lying 
in the deeper part of the matrix has a longer distance to travel to reach the surface, 
hence it results in a slower release rate with time (Ranade, 1991a and 1991b). The 
matrix type devices can be designed to deliver larger molecule drugs, such as 
peptides and proteins, by diffusion out of the matrix through inter-connected 
channels or pores within the matrix and on the surface. These channels and pores 
can be created using different approaches like solvent evaporation and phase 
separation.  
C3.2 Dissolution-controlled system 
Drug release from a dissolution-controlled system depends on two types 
of reactions: (a) degradation or erosion of the polymeric carrier and (b) cleavage 
of chemical bonds between drug and polymer molecular chain (Langer and Peppas, 
1981). The dissolution-controlled system is usually bioerodable system or 
biodegradable, where the polymer degrades through hydrolysis or enzymatic 
action into smaller segments which cannot maintain the integrity of the polymer 
matrix. The drug will diffuse out of the matrix by the same mechanism as that of 
the diffusion-controlled system before significant degradation occurs, after which 
more will escape when the surrounding polymer erodes. If degradation is 




encapsulated drug will be released with the erosion of the polymer in a predictable 
way (Mathiowitz, 1999). However, most biodegradable polymers exhibit bulk 
degradation, where all the polymer molecules that make up the matrix degrade 
simultaneously. PLGA is an example of a polymer whose degradation is 
controlled by acid. Initial degradation of this polymer begins with the outer part of 
the matrix and is relatively slow. It results in an accumulation of acidic 
by-products, which then induces a faster degradation of the polymer inside the 
matrix. Therefore, drug release occurs mainly by diffusion before bulk erosion 
occurs. A big burst drug release takes place when the structure of the matrix 
collapses. Such burst release is undesirable as the amount of drug released may 
cause drug level in the body to exceed its toxic level. However, implants made of 
biodegradable polymers need not be surgically removed because they are degraded 
and absorbed in the human body. 
C3.3 Swelling-controlled system 
A swelling-controlled system may be designed to produce zero-order 
release profile. The drug in the form of powder or solution is first dispersed in a 
polymer solution. Evaporation of the solvent results in the formation of a glassy 
polymer solid with encapsulated drug. When it is placed in a suitable dissolution 
medium, the polymer will change from its glassy state to a rubbery state. This 
transition of polymer state is due to the glass transition temperature (Tg) of the 
polymer below the room temperature. The rubber state of the polymer possesses a 
higher fraction of free volume that enables greater mobility of the drug. The drug 
diffuses out at different rates, depending on the polymer swelling dynamics, as 




first-order if the swelling front moves at a speed that is much higher than drug 
diffusion. If the reverse occurs, the release is zero-order (Korsmeyer et al., 1983).  
D. Potential use of controlled release alginate 
microspheres in transarterial chemoembolization 
Hepatocellular carcinoma (HCC) is one of the most common 
malignancies that is responsible for an estimated one million deaths annually. 
Transarterial chemoembolization (TACE) is currently the preferred choice of 
treatment for most unresectable HCC as it has been found to improve the survival 
rate of the patients (Loewe et al., 2002).  
The portal vein and hepatic artery are responsible for about 80% and 
20% of the blood supply to the liver respectively. Liver tumors are mainly 
supplied by the hepatic artery. Thus, hepatic intra-arterial chemotherapy has the 
advantage of achieving high drug concentrations in the tumor (Taylor et al., 1978). 
On the other hand, embolization of the artery will reduce its blood flow, which 
will in turn prolong drug exposure, increase drug uptake by the tumour and 
decrease systemic drug availability. Embolization will also cause hypoxemia, 
which further harms the tumour. 
As the name suggests, TACE combines embolization of the arterial 
supply of a neoplasm with controlled intra-arterial infusion of chemotherapeutic 
drugs to enhance their harmful effects on the tumour cells. However, its 
application is limited by the lack of appropriate and reliable embolization agents. 
The major problems with embolization agents are twofold. First, they may 






subsequent courses of chemotherapeutic drugs. Conversely, the effectiveness of 
TACE will not be significantly improved if the embolization agent has a short 
half-life. Second, repeated TACE may cause hepatic failure (Iwai et al., 1984). 
As alginates are biocompatible and biodegradable, they are potentially 
useful for preparing microspheres for treatment of cancer by chemoembolization. 
It was hypothesized that drug-loaded alginate microspheres of desired sizes could 
be prepared by the emulsification technique. These microspheres would have dual 
functions of embolization and controlled drug release for destruction of the 
tumour. 
OBJECTIVES
II. Objectives  
Much of past work on alginate microspheres was carried out to control 
drug release rate. Being small and porous, drug release from alginate microspheres 
was found to be relatively fast. Various methods had been tried to sustain drug 
release from alginate microspheres. These include the attempt to coat of alginate 
microspheres and the addition of a copolymer to the alginate matrix. It is 
extremely difficult to coat microparticles by the conventional spray coating 
methods without significant agglomeration. Incorporation of copolymers, such as 
hydroxypropyl methyl cellulose, was found to achieve only limited ability in 
sustaining drug release.  
It was hypothesized that alginate-based microspheres could be prepared 
as targeted delivery systems for biomaterials. The properties of the microspheres 
could be modified by different strategies to suit different applications, namely as 
an oral delivery system for controlled release of drugs and as a chemoembolization 
agent for the treatment of liver cancer. 
Hence, the objectives of this study were: 
(a) To investigate the feasibility of liquid phase coating method to 
control drug release from alginate-based microspheres. 
(b) To investigate the factors affecting the properties of alginate 
microspheres in their application as a chemoembolization agent. 
(c) To investigate poly (lactic-co-glycolic) acid as a copolymer with 




(d) To evaluate the potential of norcantharidin-loaded alginate-based 
microspheres for treatment of liver cancer. 
In this study, the influence of various formulation and processing factors 
on the physicochemical properties of the microspheres such as particle size, drug 
content, stability and drug release profiles, were determined. The therapeutic 
potential of the microspheres was evaluated by in vitro studies using cell cultures 
and by in vivo studies using rats bearing transplanted hepatoma. 
EXPERIMENTAL 
III. Experimental 
A.  Materials 
A1 Chemicals 
Sodium alginate (low viscosity, Sigma, USA) and PLGA (Resomer RG 
502H, 50:50, Mw 10,000, Boehringer Ingelheim, Germany) were used as the 
matrix polymer, PMMA (Eudragit RS100 and S100, Rohm GmbH, Germany) as 
the coat polymer and calcium chloride dihydrate (Merck, Germany) as the 
crosslinking agent. Tween 85 (Merck, Germany), Span 85 (Sigma-Aldrich, USA) 
and polyvinyl alcohol (PVA, 15,000, Fluka Chemie, Switzerland) were employed 
as the emulsifiers. Isooctane, ethyl acetate (Merck, Germany) or liquid paraffin 
(BDH, England) were used as the continuous phase in the production of 
microspheres. Ethyl acetate (Merck, Germany) and acetone (Mallinckrodt, USA) 
were used to dissolve PLGA and PMMA respectively. Tri-sodium phosphate and 
hydrochloric acid (Merck, Germany) were used to prepare the dissolution media. 
Acetonitrile and methanol (HPLC grade, Merck, Germany) were used in HPLC 
analysis. 
A2 Model drugs  
Paracetamol (pharmaceutical grade, Merck, Germany), which is 
relatively safe and readily available, was employed as a model hydrophilic drug to 
investigate the drug loading capacity and release characteristics of the 
microspheres. Norcantharidin (pharmaceutical grade, Pingyuan, China), a potent 
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hydrophilic drug that is active against primary liver cancer, was used as the 
chemotherapeutic agent. The drugs were passed through a 100-mesh sieve before 
use. 
A3 Cell cultures and related materials   
The human liver cancer cell line (SMMC-7721) was obtained from the 
Eastern Hepatobiliary Hospital, China. The cells were maintained in RPMI 1640 
culture medium (Gibco, USA), with 10% fetal calf serum (Minhai, China) and 
incubated in a humidified atmosphere of 95% air / 5% CO2. Methyl thiazolyl 
tetrazolium (MTT, Sigma, USA) and dimethyl sulfoxide (DMSO, Amresco, USA) 
were used in the determination of cell viability.  
A4 Test animals and related materials 
Healthy male New Zealand rabbits of weight 2.5-3.5 kg were obtained 
from Shanghai Research Animal Center (SRAC) for the embolization experiments. 
Male Sprague-Dawley rats, weighing 200-250 g were also obtained from SRAC 
for the pharmacodynamic study. All the test animals were housed in a 
temperature-controlled facility and provided with standard diet and water ad 
libitum. Sodium pentobarbital (2% w/v, pharmaceutical grade, Guoyao, China) 
was used as an anesthetic in the animal study. Iopromide (300 mgI/ml, 
pharmaceutical grade, Guoyao, China) was used as the contrast agent to show the 
arteries clearly in the embolization experiments. 
 41
EXPERIMENTAL 
B.  Methods 
B1 Preparation of alginate microspheres as core particles for 
liquid phase coating 
Alginate microspheres were prepared using an emulsification technique 
(Wan et al., 1992). 50 g of 3 % w/w sodium alginate solution with 3 % w/w 
paracetamol were dispersed in 75 g of isooctane containing 2.54 g of Span 85 at 
1000 rpm for 10 min using a mechanical stirrer (RW20 DZM, Ika-Werke, 
Germany). 5 g of aqueous solution containing 1.36 g of Tween 85 were added and 
stirring continued for 5 min. 20 g of 15 % w/w calcium chloride solution were 
then added and the mixture stirred for another 10 min. The microspheres were 
collected by filtration, washed thrice with 25 ml of distilled water and dried in the 
oven at 45°C to constant weight. 
B2 Liquid phase coating of alginate microspheres 
A specific amount of PMMA was dissolved in acetone. Various volumes 
of the polymer solution were tried. The polymer solution was dispersed in 200 ml 
of liquid paraffin containing 2 % w/w Span 85, at a stirring speed of 6000 rpm. 
After 1 min, a mixture composed of 0.5 g of alginate microspheres in 20 ml of 
liquid paraffin, was added to the above emulsion and stirring continued at 800 rpm 
for 3 min at room temperature to allow evaporation of acetone. The coated 
alginate microspheres were collected by filtration, washed thrice with 25 ml of 
n-hexane and dried in a vacuum oven to constant weight. The core:coat ratio and 
type of PMMA were varied to investigate the effects of these factors on the 
properties of the coated microspheres obtained (Table 2). The core:coat ratio was 
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varied by employing an appropriate volume of the polymer solution with a 
constant amount of microspheres.  
Table 2 Variables in liquid phase coating of alginate microspheres  
Batch code Type of PMMA Core to coat ratio 
(by weight) 
Control - - 
RS Eudrugit® RS 100 1:2 
S1 Eudrugit® S 100 1:1 
S2 Eudrugit® S 100 1:2 
S3 Eudrugit® S 100 1:3 
B3 Study of alginate microspheres for application as a 
chemoembolization agent  
The influence of continuous phase, surfactants, drugs and stirring speeds 
on the properties of the microspheres were investigated. 
B3.1 Preparation of alginate microspheres using isooctane  
The procedure described in Section B1 was employed. 
B3.2 Preparation of alginate microspheres using ethyl acetate 
The procedure described in Section B1 was slightly modified in order to 
produce microspheres using ethyl acetate as the continuous phase. 50 g of 5 % 
w/w sodium alginate solution with 1 % w/w drug were dispersed in 100 ml of 
ethyl acetate (EA) containing Tween 85. After 5 min, 80 g of calcium chloride 
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solution were added and stirred for another 5 min. This was followed by further 
addition of 50 g calcium chloride solution. The test mixture was stirred for another 
5 min before the microspheres were collected by filtration, washed thrice with 25 
ml of distilled water and dried in the oven at 45°C to constant weight.  
B4 Preparation of PLGA-alginate microspheres 
B4.1 Process 
PLGA-alginate microspheres (PAM) were prepared by using the multiple 
emulsion technique together with crosslinking of sodium alginate with Ca2+ 
(Figure 9). A solution of PLGA in ethyl acetate (with/without norcantharidin) was 
dispersed in 50 g of aqueous sodium alginate solution (with/without PVA) with 
the aid of a mechanical stirrer (RW20 DZM, Ika-Werke, Germany). The resultant 
primary emulsion was then dispersed in 75 g of isooctane containing 2.54 g of 
Span 85 at 1000 rpm before 5 g of aqueous solution containing 1.36 g of Tween 
85 were added and stirring continued for 5 min. Then, 20 g of 15 % w/w calcium 
chloride solution were added and stirred for 10 min. The microspheres produced 
were collected by filtration in vacuo and washed with 20 ml of distilled water 
thrice before drying in an oven at 40±1 ºC. The concentrations of PLGA and 
sodium alginate, volume of ethyl acetate, speed and duration of stirring for 
dispersion of PLGA-ethyl acetate in sodium alginate solution were varied to 




Figure 9  Flow-diagram for preparation of PLGA-alginate microspheres. 
 
For comparison with PAM, PLGA microspheres were also prepared by a 
simple emulsification method. First, 2 ml of EA containing 0.8 g of PLGA and 0.2 
g of norcantharidin was dispersed in 6 ml of aqueous solution containing 0.25 % 
w/v PVA using a vortex stirrer. The mixture was then dispersed in another 200 ml 
of aqueous solution containing 0.25 % w/v PVA using a mechanical stirrer (RW 
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20 DZM, Ika-Werke, Germany) at 400 rpm for 24 hours. The PLGA microspheres 
formed were collected by filtration in vacuo and dried under vacuum to constant 
weight in a vacuum oven (3608-1, Lab-Line, USA) at room temperature. 
B4.2 Experimental design 
An orthogonal experimental design was employed to study the impact of 
selected factors and obtain the optimal conditions for the production of 
PLGA-alginate microspheres. The microspheres were prepared according to the 
method shown in B4.1, with variation in 4 factors. The influences of the 4 factors 
at 3 levels each were investigated (Table 3). Nine combinations of conditions 
(designated as experiment number) were employed in accordance with the L9 (34) 
orthogonal experimental arrangement (Table 4). For each experiment number, 
three batches of microspheres were prepared. 
Table 3 Factors investigated in the orthogonal experimental design 
Level  Factor 
L1 L2 L3 
A, concentration of PLGA in ethyl acetate  
(%, w/w) 
10 25 50 
B, volume of ethyl acetate (ml) 1 2 5 
C, stirring speed for dispersion of PLGA-ethyl 
acetate in sodium alginate solution (rpm) 
600 800 1000 




Table 4 Experimental arrangement according to L9(34) orthogonal design matrix 
Experiment Number A B C D 
1 L 1 L 1 L 1 L 1 
2 L 1 L 2 L 2 L 2 
3 L 1 L 3 L 3 L 3 
4 L 2 L 1 L 2 L 3 
5 L 2 L 2 L 3 L 1 
6 L 2 L 3 L 1 L 2 
7 L 3 L 1 L 3 L 2 
8 L 3 L 2 L 1 L 3 
9 L 3 L 3 L 2 L 1 
 
The influences of the 4 factors on four indices (ID), namely yield (ID1, %), 
particle size (ID2, m), encapsulation efficiency (ID3, %) and burst effect (ID4, %) 
were determined. The Kx,y value (x=1,2,3,4 for different factors; y=1,2,3 for 
different levels), which is defined as the average ID value for each level of each 
factor, was calculated. The Rx value of each variable, defined by the difference 
between its maximum and minimum Kx,y values, indicates the importance of the 
factor, with a greater R value exerting greater influence. 
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B5 Determination of morphology and size distribution of 
microspheres
B5.1 Using optical microscope 
The morphology of the microspheres was examined using a light 
microscope. Dried microspheres were dispersed in distilled water and placed onto 
a glass slide. The images of the microspheres were captured by a video camera 
(CCD-IRRS, Sony, Japan) connected to a light microscope (BH2, Olympus, Japan) 
and a monitor (PVM-145E, Sony, Japan), using a software program (ImagePro). 
The size, expressed by the longest dimension of the particle, was determined. The 
mean particle size and size distribution of each formulation were determined from 
at least 200 particles.  
B5.2 Using scanning electron microscope 
The microspheres were mounted on aluminum studs, gold-coated and 
examined with a scanning electron microscope (JEOL, JSM-5200, Japan). 
B.6 Determination of drug content of microspheres 
B6.1 For paracetamol-loaded microspheres 
A known amount of microspheres was added to 100 ml of appropriate 
medium: distilled water for non-coated microspheres, sodium hydroxide solution 
for S100-coated microspheres and absolute ethanol for RS100-coated 
microspheres. The sample was placed in an ultrasonic water bath for three 
consecutive periods of 20 min with 60 min of rest in between. The sample was 
then left to stand for one day at 28-30°C. An aliquot sample of the supernatant 
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liquid was removed through a 0.45 m filter and assayed spectrophotometrically 
at 250 nm for the drug concentration (UV 1201, Shimadzu, Japan). The drug 
content was determined in triplicates. 
B6.2 For norcantharidin-loaded microspheres 
The microspheres were finely powdered and a quantity equivalent to 
about 1 mg of norcantharidin was accurately weighed and transferred into a 25-ml 
volumetric flask containing approximately 5 ml of acetonitrile. The flask was 
shaken by a vortex-mixer for three consecutive periods of 20 min with 60 min of 
rest in between. The volume was then made up with distilled water to 25 ml and 
mixed thoroughly before standing for one hour at 28-30°C. An aliquot sample of 
the supernatant liquid was removed through a 0.45 m filter and assayed by HPLC 
as described in Section B6.3. 
B6.3 High-performance liquid chromatographic (HPLC) method 
The assay of norcantharidin was carried out according to the method 
described by Gao et al. (2003), using an HPLC system (LC-2010, Shimadzu, 
Japan) with a UV detector and a Thermo Hypersil C-18 column (3, 
2.9mm×150mm). The mobile phase employed was methanol:water 15:85, adjusted 
to pH 3 using phosphoric acid. It was pre-filtered and pumped at a flow rate of 
1.0 ml/min, with the column maintained at a temperature of 30 °C. Each sample 
was injected into the column at a constant volume of 10 l for an analysis run of 
10 min. The UV detection wavelength was set at 220 nm.  
A standard curve was used for calculating the content of norcantharidin 
in the microspheres. The curve was obtained using norcantharidin concentrations 
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in the range of 0.1 to 2.0 mg/l. Different concentrations of norcantharidin, 0.5, 1.0 
and 1.5 mg/l were employed to validate intra-and inter-day precision of the assay. 
B6.4 Calculations 
Determinations were carried out in triplicate for each type of 
microspheres. The drug content was expressed as the percentage of drug 
encapsulated with respect to the weight of microspheres. The encapsulation 
efficiency was expressed as the ratio of actual to theoretical drug content. Drug 




B.7 Drug release studies 
B7.1 For paracetamol-loaded microspheres 
Drug release was studied using dissolution test (paddle method, USP 
Apparatus 2, VK6010, Vankel, USA) at 50 rpm and 37°C. The test was carried out 
by 2 methods. In the first method, drug release from an appropriate amount of 
microspheres was determined in 1000 ml of simulated gastric (SGF) or intestinal 
(SIF) fluids throughout the study. In the second method, drug release in 800 ml of 
SGF was monitored for 2 h. This was followed immediately by addition of 200 ml 
of 0.6 M tri-sodium phosphate solution to adjust the pH of the dissolution medium 
to 6.8 (SIF) and drug release was monitored for another 8 h. Filtered 5-ml samples 
 50
EXPERIMENTAL 
were collected using an auto-sampling collector (VK6000, Vankel, USA) at 
specified time intervals and assayed spectrophotometrically (UV1201, Shimadzu, 
Japan) at 250 nm for the drug. Dissolution tests were performed in triplicate and 
the results averaged. 
B7.2 For norcantharidin-loaded microspheres  
An accurately weighed amount of microspheres was introduced into a 
flask containing 250 ml of phosphate buffer solution  (PBS, pH 7.4, USP), 
agitated at 50 oscillations/min in a shaker water bath (NTS1300D, Shengyi, China) 
at 37ºC. 2-ml samples were periodically withdrawn through a 0.45 m filter and 
assayed for drug according to the HPLC method described in Section B6.3. The 
sample withdrawn was replaced with an equal volume of phosphate buffer to keep 
the volume of dissolution medium constant. All experiments were carried out in 
triplicate. The average cumulative percentage of drug released for each type of 
microspheres was calculated. 
B8 In vitro degradation studies  
The rate of degradation of the microspheres was evaluated according to a 
previously reported method (Schwarz et al., 2004). Approximately 100 mg of 
microspheres was placed in a measuring cylinder and 5 ml of 50 mM phosphate 
buffer solution (pH 7.4) was added. The microspheres were allowed to settle and 
the initial height occupied by the microspheres (h0) was marked. The measuring 
cylinder was then placed in a shaker water bath at 37°C and the corresponding 
height (ht) determined at 30-min intervals. The measuring cylinder was gently 
shaken and the microspheres were allowed to settle before measuring the height. 
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The microspheres were deemed to have degraded when no microspheres were 
detectable visually. All experiments were carried out in triplicate. The average 
(h0-ht)/h0 value in percentage at specified time interval for each type of 
microspheres was calculated.   
B9 Evaluation of growth inhibitory effect of norcantharidin-loaded 
microspheres on liver cancer cell line  
Human liver cancer cells (SMMC-7721) were grown in RPMI 1640 
medium, supplemented with 10 % fetal calf serum at 37°C in 5 % CO2 and 95 % 
air. Cells from the exponential phase of the culture were harvested and diluted to a 
cell density of about 2×104 per ml. A 100 l of the cell suspension was added to 
180 l of medium in each well of a 96-well plate, incubated at 37°C and 5 % CO2 
for 1 day. 100 l of normal saline consisting of different amounts of 
norcantharidin-loaded microspheres was then added to the respective wells and 
incubated for a specific period of time. The cells were rinsed with phosphate 
buffer solution. 20 l of PBS consisting of 5 mg/ml of methyl thiazolyl 
tetrazolium was then added and incubated for 4 h. This was followed by the 
addition of 150 l of dimethyl sulfoxide and the plate was agitated on a plate 
shaker for 10 min. The optical density (OD) of the content in each well was then 
measured at 570 nm using a bioassay reader (BioRad, USA). Controls were 
conducted using normal saline solution without norcantharidin-loaded 
microspheres. The incubation times for cells in normal saline with/without NPAM 
were varied from 24 to 48 and 72 h. The OD values reported were means obtained 









where ODtest and ODcontrol are the mean OD values for normal saline with and 
without NPAM respectively. 
B10 Evaluation of alginate microspheres for hepatic embolization 
in rabbits  
Five New Zealand rabbits weighing 2.5–3.5 kg were sedated with an 
intramuscular injection of anesthetic (2% sodium pentobarbital). A catheter was 
introduced into the femoral artery. With the aid of X-ray monitoring, the catheter 
was carefully administered into the hepatic artery. The contrast agent (Iopromide, 
300 mg/ml) was administered to illuminate the artery. An appropriate amount of 
PAM with mean size of 60 μm was dispersed in 0.5% w/w sodium 
carboxymethylcellulose solution and a dose of 10 mg microspheres per kg body 
weight of rabbit was injected. Angiography was performed at regular time 
intervals to monitor the embolization process and evaluate the effect. 
B11 Pharmacokinetics and tissue distribution 
B11.1 Preparation of bromine-substituted norcantharidin (BSN) 
250 mg of norcantharidin was dissolved in 10 ml of trichloromethane. 
The solution was then mixed with 260 mg of liquid bromine and stirred at 600 rpm 
for 24 h before filtration. The solid substance obtained was washed with 
trichloromethane, dried in a vacuum oven and analyzed by thin layer 
chromatography (TLC). An aliquot sample was filled in a capillary tube and its 
melting point determined using a melting point instrument. 
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B11.2 Preparation of 125I labeled bromine-substituted norcantharidin  
2 l of Na125I solution (18 GBq/ml) was added to 250 l of 20 % v/v 
ethanol solution containing BSN (10 mg/ml, pH 3~4) in a container. The latter 
was sealed and the mixture allowed to equilibrate for 30 min at 80-900C. An 
aliquot sample was then removed for analysis by TLC. Purification of 125I labeled 
BSN was conducted by triplicated extraction with 500 μl of dichloromethane. The 
organic phase was then separated from the aqueous phase and dried by nitrogen. 
B11.3 Care of test animals 
Male Sprague-Dawley rats (200-250 g) were used in this study. They 
were handled in accordance with the recommendations of the local animal 
protection legislation and the animal studies were approved by the Ethics 
Committee of Shanghai University of Traditional Chinese Medicine where the 
studies were conducted. A photocopy of certificate (SYXK 2005-0008) issued by 
the relevant authority for animal studies is attached in the Appendix. 
B11.4 Preparation of carcinoma cells for transplantation into rats 
Cancer cells (SMMC-7721) were revived according to the method 
employed by Ling et al. (2003). A suspension consisting of 2 ×107 cells per ml of 
normal saline was then prepared. The right lower abdomen of the rat was 
disinfected with povidone iodine and 0.5 ml of the cell suspension was injected. 
The rats were subjected to care as described previously. 5 days later, the rats were 
anesthetized to remove the ascites that had formed in their abdomens. The ascites 
were mixed with sterile water and centrifuged at 1000 rpm for 3 min. The residue 
obtained was washed with normal saline before centrifuging again. The resultant 
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residue, composed of cancer cells, was collected. It was diluted to cell density of 1 
×106 cells per ml of normal saline in the preparation of liver cancer model for 
study. 
B11.5 Transplantation of cancer cells in rats to prepare liver cancer 
model for study 
The rats were transplanted with the carcinoma cells in accordance with 
the technique employed by Ling et al. (2003). They were fasted for 12 hours, then 
anesthetized by injection of 2 % v/w sodium pentobarbital into their abdomen, at a 
dose of 40 mg/kg. Under aseptic condition, the abdomen was opened to expose the 
liver. 0.05 ml of the suspension consisting of 1×106 cancer cells per ml was 
injected into the left lobe of the liver. The incisal opening was then sutured and the 
rats were allowed to recuperate for 10 days before further tests were carried out.  
B11.6 Study on pharmacokinetics and tissue distribution of norcantharidin 
The 125I-labeled BSN-loaded PLGA-alginate microspheres (INPAM) 
were prepared according to the method described in Section B 4.1. 
10 days after recovery from surgery, 64 rats were randomly divided 
equally into 2 groups: 125I-BSN solution group and INPAM group. The test 
samples in 0.5 % sodium carboxymethylcellulose solution were administered at a 
dose of 30 microcurie (ci) for each rat. The rats were sacrificed at different time 
intervals. Samples consisting of blood and entire spleen, liver, kidney, heart, lung, 
brain as well as carcinoma tissues were collected for analysis. All these samples 
were weighed and determined for radioactivity (rpm, radiocounting per minute). 
The ratio (%) of radioactivity of sample to total injected quantity (30 ci) was 
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determined. The drug targeting index, DTI and drug selective index, DSI were 
calculated as follows: 
 
B12 Pharmacodynamics study  
Sixty-four rats that were successfully transplanted with hepatoma were 
employed. The rats were divided into four groups of 16. With the aid of a 
binocular microscope (YZ-20T4, Suzhou Medical Device Co., China) for 
laparectomy, a silastic microcatheter was retrogradely inserted into the 
gastroduodenal artery leading to the hepatic artery. The 4 groups were 
administered with normal saline, norcantharidin solution, blank PLGA-alginate 
microspheres and norcantharidin-loaded PLGA-alginate microspheres respectively, 
by injection through the microcatheter. Seven days after the injection, six rats in 
each group were chosen randomly for evaluation of survival time. Survival rate 





 ………………………………equation 5 
where STcontrol and STtest are the average survival time (days) for the rats 
administered with normal saline and with the test agent respectively.  
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The remaining rats in each group were sacrificed after treatment and their 
tumors were removed for examination. The longest (a) and the shortest (b) vertical 
dimensions of the tumor were measured. The size (V) and growth rate (GR) of the 




 …………………………………………. .…….. equation 6 
Tumor size after 7 days of treatment 
Tumor size before treatment
GR 
…… .…….…. equation 7 
A representative formalin-fixed, paraffin-embedded tissue block from 
each tumor was analyzed by conventional hematoxylin-eosin (HE) staining. The 
degree of necrosis in the tumor was determined visually and graded as follows: -/+ 
(no necrosis present or slight necrosis in fragmentis), ++ (mid-range necrosis, 
absence of nuclei from many cells with or without massive cytoplasmic damage) 
and +++ (severe necrosis, total loss of cytoplasm of the carcinoma cells). 
C.  Mathematical models and statistical analysis 
C1 Mathematical models 
The drug release kinetics of the coated microspheres was determined by 
fitting the dissolution data to the following release models. 
Korsmeyer-Peppas equation 




………………………………………… ....… equation 8 
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where Mt/M  is the fraction of drug released at time t, K is a constant and n is the 
exponent indicative of release mechanism.  
Zero-order equation  
 …………………………………………….equation 9
where Q is the amount of drug remaining at time t, Q0 is the amount of drug at t=0 
and K0 is the zero-order release constant.  
First-order equation  
0 1ln Q ln Q  K t   …………………………………..…..equation 10
where K1 is the first-order release constant.  
Higuchi square root equation 
1 2
H  tM K t   ………………………..………………..equation 11
where Mt is the amount of drug released at time t and KH is the Higuchi rate 
constant.  
C2 Statistical analysis 
Data was reported as mean ± standard deviation (SD). Differences were 
assessed for significance using the one-way ANOVA or unpaired t-tests as 
appropriate. The level of significance was set at  = 0.05.  
Multilinear regression was performed to determine the impact of time 




to determine the relationships among the four variables studied in the orthogonal 
experimental design. Statistical software SPSS (Version 10) was used to calculate 
multiple regression equations. 
Other statistical analyses were also carried out by SPSS program. Results 
were subjected to variance test, chi-square test, Mann-Whitney test and linear 
regression where appropriate. A p value <0.05 based on a two-tailed test was 
considered statistically significant. 
RESULTS AND DISCUSSION 
IV. Results and discussion  
This study consisted of 4 parts. Part 1 reports the work carried out on 
liquid phase coating of alginate microspheres. This was a study undertaken to 
develop an oral delivery system for controlled drug release. Part 2 reports the 
influences of various formulation and process parameters on the properties of 
alginate microspheres prepared for chemoembolization. In Part 3, the development 
of PLGA-alginate microspheres as chemoembolization agents is reported. Part 4 
covers the pharmacokinetics/pharmacodynamics study and tissue distribution of 
PLGA-alginate microspheres. 
Part 1: Liquid phase coating of alginate microspheres 
The objective of this part of the study was to investigate the feasibility of 
a liquid phase coating method in the development of alginate-based microspheres 
for release of drug at a target site, namely the small intestine. Hence, the 
microspheres should be able to retain and protect the drug in the acidic medium of 
the stomach. However, they should be able to release the drug in the intestinal 
medium. Paracetamol was chosen as a model hydrophilic drug and polymethyl 
methacrylate (PMMA) as the coat polymer. The mechanism of formation of these 
coated microspheres was studied. The effects of the core:coat ratio and type of 
PMMA coat polymer on particle size, drug loss during coating, as well as release 
characteristics of the microspheres in simulated gastric and intestinal fluids were 
also investigated.  
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1.1 Coating process 
In the conventional solvent-evaporation technique, cores are initially 
dispersed in the organic solvent in which the coat polymer was previously 
dissolved (Figure 10). The resultant mixture was then dispersed in an oil phase 
(continuous phase) for a prolonged period of time to allow the evaporation of 
solvent, leading to the deposition of the polymer on the cores (Lee and Min, 1996). 
This method is not suitable for paracetamol-loaded alginate microspheres because 
of the high solubility of paracetamol in acetone (9.78 g/100 ml), which was used 
to dissolve PMMA.  
 
Figure 10 Comparison of the conventional solvent-evaporation technique and 
liquid phase coating technique. 
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Hence, in this study, the method employed to coat the alginate 
microspheres was modified to minimize contact between the cores (alginate 
microspheres) and the organic solvent (acetone). The coating procedure consisted 
of two stages (Figure 10). In the first stage, the polymer was dissolved in acetone 
and the resultant solution dispersed in liquid paraffin. Acetone was chosen because 
it dissolved PMMA readily and exhibited slow evaporation in liquid paraffin. The 
latter property enabled a more controlled coating of the cores. Span 85 and a high 
stirring speed were employed to ensure that the polymer solution remained as a 
fine dispersion in liquid paraffin, forming the coating emulsion. In the second 
stage, the cores were first dispersed in a small volume of liquid paraffin before 
adding to the coating emulsion.  
Microscopic examination of the samples taken at different time intervals 
suggested the following coating mechanisms (Figure 11). At the beginning, the 
PMMA solution was dispersed as fine droplets in liquid paraffin (Figure 11a). 
Introduction of alginate microspheres affected the stability of the coating emulsion, 
resulting in gradual coalescence of the droplets of PMMA solution. The 
evaporation of acetone increased the polymer concentration and viscosity of the 
droplets. Some of these droplets were attracted to the surface of alginate 
microspheres (Figure 11b). The presence of viscous PMMA solution on the 
microsphere surface made the microspheres tacky and stick to one another when 
they collided during the coating process (Figure 11c). Stirring at 800 rpm kept 
particles in motion imparted a rounding effect on the agglomerates (Figure 11d).  
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(a) 
                             
 
(b) 
                            
Figure 11  Photographs showing the coating mechanism:  (a) Droplets of 
PMMA solution in the coating emulsion (b) Adhesion of PMMA 
droplets to microspheres and coalescence of the droplets to form 
coats around the microspheres. Bar scale equals 40 m. 
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(c) 
                         
 
(d) 
                         
Figure 11 (cont’d) Photographs showing the coating mechanism: (c) 
Agglomeration of microspheres (d) Formation of solid coat around 
agglomerated microspheres with evaporation of acetone. Bar scale 
equals 40 m. 
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 As the acetone continued to evaporate, PMMA droplets precipitated on 
the microspheres’ surfaces to form coats. Some free precipitates of PMMA were 
also found at the end of the coating process. They were markedly smaller in size 
than the original uncoated microspheres (mean size, 85.6 μm). The size of the 
coated microspheres was markedly larger than that of the uncoated microspheres, 
indicating significant agglomeration of microspheres during the coating process 
(Figure 12).  
 
Figure 12  Size distribution of PMMA-coated alginate microspheres 
(core:coat=1:2).  
 
1.2 Particle size and drug encapsulation efficiency of the coated 
microspheres
Two types of PMMA (Eudragit® RS 100 and S100) were used as the 
coating polymer. The 2 different types of coated microspheres obtained showed 
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significantly different size distributions (Figure 12). The mean sizes of the coated 
microspheres, which ranged from 354 to 807 m, were markedly larger than that 
of the non-coated microspheres (85.6 m) and depended on the type of PMMA 
used (Table 5). At the same core:coat ratio, S100-coated microspheres were 
markedly smaller than the RS100-coated microspheres (Figure 12). As similar 
alginate cores were used for the coating process, this finding indicated that RS100 
caused a greater extent of microsphere agglomeration. Preliminary studies showed 
that the RS100 solution had a higher viscosity than the S100 solution at the same 
concentration of 2.5 % w/v polymer in acetone. Thus, RS100 would be expected 
to impart a greater degree of tackiness, resulting in a higher level of microsphere 
agglomeration. 
For the liquid phase coating process, various amounts of PMMA solution 
were used to produce the different core:coat ratios. The proportion of S100 used 
for coating was varied from 50 % to 75 % but the mean size of the coated 
microspheres obtained differed by only about 4 %. This showed that core:coat 
ratio had minimal effect on the mean size of the coated microspheres.  
The extent of drug loss after coating ranged from 8 % to 16 % and varied 
with the type of PMMA and core:coat ratio (Table 5). In preliminary studies, 
alginate microspheres coated with RS100 using the conventional 
solvent-evaporation technique resulted in a drug loss of 32.6 %. This was 
attributed to direct contact of the microspheres with a greater amount of acetone, 
enabling higher extraction of the drug from the microspheres by the organic 
solvent (Figure 10). Hence, the strategy of coating alginate microspheres in a 
dispersion of PMMA solution in liquid paraffin had successfully reduced contact 
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between the microspheres and the organic solvent, thereby markedly reducing 
drug loss during the coating process. 
Table 5 Characteristics of alginate microspheres with and without PMMA coat 
Batch 
code 
Type of  
PMMA 




Drug loss, L  
(%) 
Control - - 85.6±7.4 - 
RS RS 100 1:2 807.4±60.1 7.8±0.34 
S1 S 100 1:1 369.2±21.5 11.3±0.51 
S2 S 100 1:2 373.9±17.9 16.0±0.32 
S3 S 100 1:3 354.0±13.1 9.1±0.32 
 
1.3 Effect of pH on drug release from coated microspheres 
Drug release from the non-coated alginate microspheres was rapid, with 
more than 90 % of drug released within 45 min. Coating these microspheres with 
RS100 markedly retarded the release of drug to comparable extents in SGF and 
SIF (Figure 13). The release rate of S100-coated microspheres was sensitive to the 
pH of the dissolution medium. Drug release was reduced markedly in SGF, but to 
a smaller extent in SIF. The S100-coated microspheres showed more sustained 










Figure 13  Release of paracetamol from alginate microspheres with and without 
PMMA coat: (a) in simulated gastric fluid, (b) in simulated intestinal 
fluid. 
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The proposed drug release mechanisms for RS100-coated and 
S100-coated microspheres are illustrated in Figure 13a and 13b respectively. Intact 
and swollen RS100-coated microspheres were recovered from SGF and SIF at the 
end of the dissolution tests. RS100 is known to swell but not dissolve in acidic or 
alkaline media (Lehmann, 1999). Although the polymer coat swelled, it was not 
very permeable to the drug as shown by the retarded drug release (Figure 13). 
Coating the microspheres with S100 retarded drug release in SGF to a markedly 
greater extent than in SIF (Figure 14). The reason is that S100 is only soluble at 
around pH 7 but it produces an insoluble, water-impermeable coat in an acidic 
medium (Lehmann, 1999).  Hence, the polymer coat around the microspheres 
would erode and release the drug faster in SIF than in SGF. Dissolution results of 
S100-coated microspheres showed a much more retarded drug release in SGF 
compared to non-coated and RS100-coated microspheres (Figure 14). 
 
RS100-coated alginate microspheres 
S100-coated alginate microspheres 
Figure 14  Scheme of the possible mechanisms of drug release. 
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1.4 Drug release behavior of coated microspheres in changing pH 
condition
Further dissolution tests were carried out using SGF in the first 2 h and 
SIF in the next 8 h in an attempt to simulate the changing pH conditions in the 
gastrointestinal tract. As observed previously, drug release from the coated 
microspheres was markedly slower as compared to the uncoated microspheres. 
The S100-coated microspheres showed more sustained drug release than the 
RS100-coated microspheres. The release profiles of the microspheres showed that 
the drug release rate was affected by the amount of polymer employed for coating 
(Figure 15).  
 
Figure 15  Release of paracetamol from alginate microspheres in simulated 
gastric fluid (0-2 h) and simulated intestinal fluid (2-10 h). 
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The time taken for 50 % of the encapsulated drug to be released, T50%, 
was determined. The dissolution T50% values were found to increase in the 
following order: S3 (3.5 h) > S2 (1.6 h) > S1 (0.8 h), indicating that drug release 
was retarded by decreasing core:coat ratio. S1 and S2 microspheres showed more 
than 50 % drug released in SGF. The relatively rapid drug release in SGF could be 
attributed to insufficient coating polymer to form a continuous coat around the 
core microspheres. Further evaluation of microspheres coated with different 
amounts of RS100 was not conducted because of the rather rapid overall release of 
drug despite employing a core:coat ratio of 1:2. This indicated that the coating was 
not efficiently layered or there was insufficient affinity between the microspheres 
and coating polymer to bring about effective and uniform coatings. 
1.5 Kinetics of drug release 
The dissolution data obtained were analyzed using various release 
models (Table 6). From the value of the correlation coefficient (r), drug release 
kinetics of RS and S2 microspheres were better described by Higuchi’s square root 
model than first order release or zero order release models. This suggested that the 
drug was released mainly by diffusion. Compared to RS microspheres, drug 
release from S2 microspheres in SIF showed a lower conformance to Higuchi’s 
model, probably due to erosion of S100 in SIF (Figure 14).  
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Table 6  Drug release kinetics of the microspheres with and without PMMA coat 
Correlation coefficient (r) 
Higuchi’s model First order release 
model 




SGF SIF SGF/SIF SGF SIF SGF/SIF SGF SIF SGF/SIF
Control 0.655 0.661 0.756 0.648 0.825 0.837 0.453 0.455 0.538 
RS 0.934 0.948 0.907 0.781 0.785 0.873 0.801 0.823 0.740 
S2 0.983 0.858 0.980 0.854 0.647 0.873 0.918 0.688 0.902 
 
Korsmeyer-Peppas model  (in SGF/SIF) 
Batch code 
n k T50% (h) 
RS 0.19 66.59 0.22 
S1 0.28 53.17 0.80 
S2 0.42 40.65 1.63 
S3 0.66 22.16 3.48 
 
The release data were also analyzed using the Korsmeyer-Peppas model. 
According to this model, an n value of unity indicates zero order drug release 
while n value of 0.5 indicates drug release by Fickian diffusion mechanism 
(Harland and Peppas, 1989). If drug diffusion is affected by other factors such as 
erosion, the n value will lie between 0.5 and 1.0.  
The n value of RS, S1 and S2 were less than 0.5, supporting the above 
findings that release kinetics were not zero order. It was observed that the n value 
of the S100-coated microspheres increased in the following order: S1 < S2 < S3, 
indicating a gradual change in release kinetics by varying core:coat ratios. The 
decreasing k value but increasing T50% value with decreasing core:coat ratio 
showed that drug release was retarded by increasing the proportion of coating 
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polymer. The T50% values of the coated microspheres showed that it was possible 
to control drug release from the microspheres by proper selection of the type and 
amount of coating polymer.  
1.6 Summary of Part 1 of study 
Liquid phase coating, based on a modified solvent-evaporation technique, 
markedly reduced drug loss from microsphere cores to the continuous liquid phase 
during coating. The coated microspheres showed markedly reduced drug release 
compared to the non-coated ones. The release mechanism and rate were affected 
by the type of PMMA, core:coat ratio and dissolution media. The liquid phase 
coating technique developed offers a novel method of coating microspheres with 
markedly reduced drug loss and possible controlled drug release. 
However, it should be acknowledged that the agglomeration of core 
microspheres, as well as the formation of blank PMMA microspheres in the liquid 
phase coating process was not ideal. It will be a considerable challenge to produce 
individually coated core microspheres and to avoid the formation of blank PMMA 
microparticles. Being much smaller in size, the later can be separated by sieving 
but this may inevitably remove some coated microspheres, resulting in some loss 
in yield.  
RESULTS AND DISCUSSION 
Part 2: Study of alginate microspheres for application 
as a chemoembolization agent  
The objective of this part of the study was to explore the feasibility of 
alginate microspheres as a chemoembolization agent for the treatment of liver 
cancer. Properties of the microspheres, such as particle size, drug load, release 
characteristics and rate of degradation, were expected to affect their function in 
chemoembolization. Hence, the influences of various factors on these properties of 
alginate microspheres produced by emulsification were investigated. The effects 
of selected formulations on inhibition of liver cancer cells and arterial 
embolization were also evaluated. 
Both paracetamol and norcantharidin were employed as model drugs in 
this study. Unlike paracetamol, it is much more difficult to assay for 
norcantharidin. This section begins with the discussion on the validation of the 
HPLC assay of norcantharidin, which was necessary in the study of 
norcantharidin-loaded alginate microspheres for use as a chemoembolization 
agent. 
2.1 Validation of HPLC assay of norcantharidin 
2.1.1 Linearity and limit of quantitation 
Assay linearity was evaluated based on the analysis of calibration 
standards prepared. The peak area corresponding to each concentration of 
norcantharidin was determined in triplicates. The six-point calibration curve 
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obtained was linear over the range of 0.1-2 mg/l norcantharidin 
(A=2.06×107C-1.62×104, r2=0.9997), where A is the peak area and C is the 
concentration. The limit of quantitation (LOQ) was determined as the lowest point 
on the calibration curve that could be analyzed with percentage error within 20%. 
For norcantharidin, the LOQ values were found to be 0.1 mg/l, which was 
comparable to a previous published study (Gao et al. 2003). 
2.1.2 Precision and recovery 
Intra-day precision of the assay was studied by triplicated analyses (n=3) 
of samples at each of three spiked concentrations within the same day. Inter-day 
precision of the method was determined at the same three concentrations used in 
the study of intra-day precision, with samples at each concentration being 
analyzed in triplicates over three consecutive days (n=3). The precision of the 
sample analysis was studied at concentrations of 0.5, 1 and 1.5 mg/l. The relative 
standard deviation (R.S.D.) values for peak areas of norcantharidin were less than 
2.5% for intra-day precision and not more than 5.0% for inter-day precision (Table 
7). The analytical recovery is defined as the analyzed concentration expressed as a 
percentage of the actual spiked concentration. As shown in Table 8, the mean 
analytical recovery of norcantharidin was within 90-110%.  
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Drug concentration  
(mg/l) 
Intra-day (n=3) Inter-day (n=3) 
0.5 2.34 2.53 
1.0 1.67 2.65 
1.5 1.51 3.63 
 
Table 8 Accuracy of the norcantharidin assay 
Drug concentration  
(mg/l) 
Spiked  Analyzed  








0.5 0.48 ± 0.02  1.44 96.0 
1.0 0.95 ± 0.16  1.27 95.0 
1.5 1.60 ± 0.09 0.96 106.7 
2.2 Influence of continuous phase on the production of alginate 
microspheres
Calcium alginate microspheres containing paracetamol were successfully 
produced by the emulsification technique using isooctane as the immiscible 
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continuous phase. The photograph of the microspheres is shown in Figure 16. The 
alginate microspheres were generally discrete and spherical, with mean size of 
about 85 μm and drug content of 13.42 %. Dissolution study showed rapid release 
of the drug in both SGF and SIF (Figure 17). Rapid release of sulphaguanidine 
from alginate microspheres in distilled water was also observed in earlier studies 
(Chan, et al., 1997). 
 
 
Figure 16  Photograph of alginate microspheres produced using isooctane, 
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Figure 17   Drug release profiles in simulated gastric (SGF) and intestinal (SIF) 
fluids of alginate microspheres produced using isooctane as 
continuous phase.  
 
However, toxicological information of isooctane is limited. A 
permissible exposure level of below 300 ppm for isooctane is recommended (ICH, 
1995). In contrast, the toxicity of ethyl acetate is low and ethyl acetate has not 
been shown to be a human carcinogen and reproductive or developmental toxin. 
Ethyl acetate is a permitted direct food additive by FDA (ICH, 1995). Hence, its 
suitability as the continuous phase for the production of alginate microspheres was 
investigated. 
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Calcium alginate microspheres were also successfully formed using ethyl 
acetate as the continuous phase. The stirring speed could be reduced to 600 rpm 
without producing significant aggregation of microspheres. In an attempt to 
increase the microsphere yield, the concentration of sodium alginate was increased 
from 3% w/w to 5% w/w. The amount of drug was proportionally increased to 5% 
w/w while the amount of continuous phase was increased to 100 ml to better 
accommodate the larger amount of dispersed phase.  
 
The morphology of the alginate microspheres thus obtained is shown in 
Figure 18. The microspheres were generally discrete and spherical, with a mean 
size of about 200 μm. The microspheres were markedly larger than those produced 
using isooctane. The dried microspheres appeared shrunken and showed 
significant indentations on their surfaces, indicating that the matrix was not very 
rigid and deformed upon the loss of water content during drying. Ethyl acetate was 
found to be potentially useful as the continuous phase for the production of 
alginate microspheres by emulsification. 
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Figure 18  Morphology of blank alginate microspheres at different stages of the 
production process using 5 % w/w sodium alginate, ethyl acetate and 
2.5 % w/w Tween 85 at 600 rpm (a: after cross-linking with calcium 
chloride; b: after filtration; c: after drying). 
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2.3 Influence of surfactant on the production of alginate microspheres 
with ethyl acetate 
The type of surfactants and their HLB values are known to play 
important roles in emulsification. Previous studies showed that a combination of 
hydrophilic and lipophilic surfactants with appropriate HLB value was critical for 
the formation of discrete and spherical alginate microspheres using isooctane 
(Wan et al., 1992). In this study, it was found that the formation of microspheres 
using ethyl acetate was not possible without a surfactant or with Span 85 alone.  
However, Tween 85 alone was sufficient to aid in the dispersion of the 
aqueous sodium alginate phase as fine globules in ethyl acetate. The required 
concentration of Tween 85, with respect to the weight of ethyl acetate, was also 
markedly less than that needed for isooctane. The concentration of Tween 85 was 
varied to study its influence on the properties of microspheres obtained. The mean 
size of the microspheres was found to decrease significantly (p<0.05) with 
increasing concentration of Tween 85 (Table 9).  
Table 9   Properties of microspheres produced with 5 % w/w sodium alginate, 
ethyl acetate and different concentrations of Tween 85 at 600 rpm  
Concentration of 
Tween 85 (% w/w) 
Mean size 




 (% w/w) 
0.5 246±28 1.96 2.04 
1.5 231±17 2.65 2.23 
2.5 226±13 2.72 2.28 
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The above results could be attributed to greater emulsifying efficiency of 
a higher concentration of surfactant. At a higher concentration of Tween 85, less 
alginate adhered to the stirrer and wall of the vessel, which aptly accounted for the 
higher harvested yield. Drug content was generally low due to the solubility of the 
model drug, paracetamol, in ethyl acetate. Hence, this aspect should be an 
important consideration in the selection of an appropriate continuous phase. 
Nonetheless, drug content was significantly higher (p<0.05) when the 
concentration of Tween 85 was increased from 0.5% to 1.5% w/w. Further 
increase of the surfactant concentration to 2.5% w/w did not increase drug content 
significantly (p>0.05). Being surface active, Tween 85 molecules gathered at the 
interfaces between sodium alginate droplets and ethyl acetate. The results 
suggested that the hydrophilic surfactant molecules hindered partitioning of the 
drug between the sodium alginate droplets and the continuous phase of ethyl 
acetate during the production of microspheres. During washing, the surfactant 
molecules would leach from the microspheres to the aqueous medium, where they 
would lower surface tension and enhance drug loss from the microspheres by 
increasing drug solubility. The drug content was thus determined by the balance of 
these two opposing effects. 
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2.4 Influence of stirring speed on the production of alginate 
microspheres
The stirring speed is one of the most commonly used parameters of the 
emulsification technique to modify microsphere size (Mateovic et al., 2002). In 
this part of study, the effects of stirring speed on the production of alginate 
microspheres using either ethyl acetate or isooctane were investigated. From 
preliminary studies, different ranges of stirring speeds were employed to avoid 
marked aggregation of microspheres. 
In the production of alginate microspheres with ethyl acetate as the 
continuous phase, mean size of the microspheres decreased with increasing 
stirring speed before leveling off (Figure 19). At low stirring speeds of 200 and 
400 rpm, more irregular microspheres were formed. At 600 and 800 rpm, most of 
the microspheres were discrete and spherical and their mean sizes were 
comparable. The mean particle size was also found to decrease with increasing 
stirring speed when isooctane was used. This trend can be explained by more 
effective emulsification at higher stirring speeds, thus producing smaller droplets 
of sodium alginate solution that led to the formation of smaller microspheres. The 
higher shear forces with higher stirring speeds also aided in breaking up the 
disperse phase as well as to reduce the likelihood of aggregation. A fairly linear 
relationship was observed between the mean size and stirring speed for isooctane 
(r=0.980, Figure 19). The size distribution was typically unimodal with a spread of 
about 30.1 μm. Smaller microspheres with mean size of 48.8 μm were produced at 
higher stirring speed of 1000 rpm whereas larger microspheres of mean size 96.4 
μm were produced with 700 rpm. 
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Figure 19  Effect of stirring speed on the mean size of alginate microspheres. 
 
For embolization of different types of tumor, particles of different size 
ranges are required. For example, microspheres of size between 20 and 50 μm 
were found to be suitable for embolization of liver tumors. However, this size 
range was too small for embolization of head-and-neck tumors because 50% of the 
radioactivity spilled into the lungs (van Es et al., 2001). The diameters of arteries 
in a Walker 256 carcinoma ranged from 25-75 μm while those of normal 
capillaries ranged from 1-8 μm (Meade et al., 1987). Small microspheres (<10 μm) 
were found to be captured in liver tumor capillaries while large ones (>100 μm) 
could hardly reach them (vas Es et al., 2001). Embolization studies of liver tumors 
also indicated that an appropriate size distribution of the embolizing particles was 
preferred as the target vessels have varying dimensions. Frequently-used 
degradable starch microspheres (Spherex®) have uniform size which was found to 
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limit their application (Fujiwara et al., 2000). On the other hand, alginate 
microspheres prepared by the emulsification method showed a certain size 
distribution and the mean size could be controlled by employing a suitable stirring 
speed. Thus they are more desirable for embolization.  
Alginate microspheres produced using isooctane were preferred to ethyl 
acetate as their sizes could be more effectively modified by varying the stirring 
speed (Figure 19). Hence, the former was further characterized. Closer 
examination of these microspheres under the scanning electron microscope 
showed a relatively rough and porous surface (Figure 20). This accounted for their 
rapid drug release which will be discussed in a later section. The drug content of 
the paracetamol-loaded alginate microspheres was found to increase 
proportionally with an increase in stirring speed (r=0.987). However, the change in 
drug content was marginal compared with the change in size of microspheres 
when the stirring speed was raised (Table 10). 
 
Table 10 Mean size and paracetamol content of alginate microspheres produced 








700 96.38 ± 5.70 6.38 ± 1.07 
800 72.29 ± 8.72 6.64 ± 0.93 
900 59.10 ± 6.33 6.74 ± 0.76 
1000 48.75 ± 4.95 6.98 ± 0.98 
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Figure 20   SEM photomicrographs of paracetamol-loaded alginate microsphere. 
(a) produced with 3 % w/w sodium alginate and isooctane and (b) the 
microsphere surface. 
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2.5 Influence of drug properties on the production of alginate 
microspheres using isooctane 
Both paracetamol-loaded and norcantharidin-loaded alginate 
microspheres were successfully formed by the emulsification technique. 
Paracetamol-loaded and norcantharidin-loaded alginate microspheres produced at 
900 rpm showed similar surface morphologies. They were spherical and discrete 
when hydrated in water. SEM photographs showed a relatively rough and porous 
surface which is commonly observed in microspheres produced by the external 
gelation method (Aslani and Kennedy, 1996). The emulsification technique 
employed in this study to produce alginate microspheres was based on the external 
gelation method where calcium chloride was added to droplets of sodium alginate 
solution dispersed in isooctane. 
Norcantharidin-loaded alginate microspheres were smaller in size and 
had lower drug content than paracetamol-loaded alginate microspheres (Table 11). 
This could be attributed to the higher solubility of norcantharidin (9.3g/100 ml at 
20°C) than paracetamol (1.4g/100 ml at 20°C) in water. During the process of 
microencapsulation, a large amount of norcantharidin was expected to be lost to 
the aqueous phase. Thus, the resultant microspheres had lower drug content. 
Since both norcantharidin and paracetamol have relatively high 
solubilities in water, their encapsulation efficiencies were relatively low. 
Nonetheless, norcantharidin is a very potent drug and needed only in small 
quantities for its pharmaceutical action and the dose could be adjusted by varying 
the amount of microspheres used. 
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Table 11  Physical properties of norcantharidin-loaded and paracetamol-loaded 
alginate microspheres produced using 3 % w/w sodium alginate 















2.84±0.19 2.56±0.98 5.12±0.93 43.22±5.34 
Paracetamol-loaded 
microspheres 
3.11±0.12 6.74±1.05 13.48±0.95 59.10±6.19 
 
2.6 Drug release from alginate microspheres 
Drug release profiles of alginate microspheres produced with ethyl 
acetate or isooctane were compared by dissolution runs in distilled water (Figure 
21). For both types of microspheres, more than 80 % of paracetamol was released 
within 30 min. The time taken for 75% of the drug to be released from the 
microspheres (T75%) was 12.6 min and 14.2 min for isooctane and ethyl acetate 
respectively. Drug release from the microspheres produced with ethyl acetate was 
slightly slower. The mean sizes of the microspheres produced in isooctane or ethyl 
acetate were 59.1 and 231 m respectively. Hence, the slower release was most 
likely due to the larger particle size of microspheres prepared with ethyl acetate.  
Drug release from paracetamol-loaded and norcantharidin-loaded 
alginate microspheres produced with isooctane was investigated by dissolution in 
PBS (pH 7.4) in an attempt to simulate physiological fluid. Release rates of 
paracetamol and norcantharidin were relatively fast, with 90% of both drugs 
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released within 60 min (Figure 21). Such rapid drug release from alginate 
microspheres was also observed in earlier studies (Wan et al., 1992).  
 
Figure 21  Drug release profiles of alginate microspheres containing different 
drugs, prepared with isooctane or ethyl acetate, with phosphate buffer 
solution (PBS) or distilled water as the dissolution media. 
 
Earlier investigations showed that drug was released more slowly from 
larger microspheres as they had low surface to volume ratio and longer pathways 
for drug diffusion. Paracetamol is less soluble (0.65 g/100ml at 25 oC) than 
norcantharidin (8.95 g/100ml at 25 oC) in PBS. In spite of paracetamol having a 
lower solubility in PBS and entrapped within larger microspheres (Table 12), it 
was released significantly faster than norcantharidin-loaded microspheres (p<0.05). 
A comparison of the drug content showed that paracetamol-loaded alginate 
microspheres (6.74%) contained more drug than norcantharidin-loaded alginate 
microspheres (2.56%). The concentrations of paracetamol and norcantharidin were 
kept at a constant level of 3% w/w during the production of the microspheres. This 
drug concentration was higher than the solubility of paracetamol but lower than 
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that of norcantharidin. Therefore, excess paracetamol would exist as solid drug 
particles while norcantharidin would all be dissolved in the sodium alginate 
droplets. The presence of undissolved crystals would hinder the formation of a 
polymeric matrix, thereby reducing the diffusion barrier properties and increasing 
the porosity of the polymer matrix formed. This aptly explained the comparatively 
faster release of paracetamol from the microspheres. The slower release of 
norcantharidin is desirable as it would minimize drug loss during the conveyance 
period of the microspheres in the blood stream to the target site.  
 
Table 12  Drug release profiles of paracetamol-loaded alginate microspheres with 
different mean size 
Time (min) 





Drug released in PBS (%) 
700 96.4±5.7 64.8±1.6 79.2±1.1 87.2±1.9 90.4±1.0 92.2±0.7
800 72.3±8.7 78.3±1.7 84.4±2.0 88.3±1.1 91.0±1.8 94.9±0.5
900 59.1±6.3 83.7±0.7 89.5±0.9 91.8±0.5 92.7±1.1 95.1±0.8
1000 48.8±5.0 87.6±0.5 91.8±1.7 93.2±1.3 94.9±0.8 97.6±0.6
r 0.957 0.987 0.978 0.972 0.961 Linear 
regression of 
drug release 
profile k 0.074 0.043 0.022 0.015 0.016 
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2.7 In vitro degradation studies of alginate microspheres 
The in vitro degradation studies were conducted in PBS (pH 7.4) at 37°C 
to simulate the physiological conditions encountered by the microspheres. 
Negative (h0-ht)/h0 values indicated swelling of microspheres in PBS while 
positive values indicated degradation. When immersed in PBS for 5 min, all the 
batches of paracetamol-loaded alginate microspheres swelled by about 4 times 
their original size (Figure 22). Their volume gradually decreased, indicating the 
onset of degradation. Alginate microspheres degrade by conversion of its insoluble 
calcium salt to a soluble form by ion exchange in PBS. The microspheres with 
smallest mean size (48.75 μm) disappeared in 90 min while the rest within 120 
min. The rate of degradation was affected by the size of the microspheres, with 
smaller microspheres degrading faster than larger ones due to larger surface area 
to volume available for ion exchange. 
 
Figure 22  The (h0-ht)/h0 values for paracetamol-loaded alginate microspheres of 
different mean sizes.  
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Very rapid degradation of the embolization agent will lead to 
recanalization, while a more persistent agent will lead to prolonged occlusions. 
The latter may induce the formation of new vessels to bypass the occluded ones or 
cause necrosis of the target organ. Animal studies were necessary to determine the 
suitability of the alginate microspheres for embolization. 
2.8 Growth inhibitory effect of norcantharidin-loaded alginate 
microspheres on liver cancer cells 
The effects of blank (BAM) and norcantharidin-loaded alginate 
microspheres (NAM) on the growth of liver cancer cells were examined. The 
NAM used contained 2.56 % w/w norcantharidin. The cancer cells were exposed 
to varying concentrations of NAM for different periods of time. The blank 
microspheres exhibited insignificant growth inhibitory effects. In contrast, 
norcantharidin-loaded alginate microspheres exhibited a marked inhibitory effect, 
which was dependent on both contact time and microsphere concentration (Figure 
23).  
Multilinear regression was performed with inhibitory effect as a 
dependent variable and NAM concentration and contact time as independent 
variables in order to examine impact of these parameters on growth inhibition of 
the cancer cells. A larger coefficient for contact time (0.474, p<0.001) as 
compared to that for NAM concentration (0.324, p<0.001) suggested greater 
influence of the former parameter over the latter under the study conditions. 
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Figure 23  Growth inhibitory effects of norcantharidin-loaded alginate 
microspheres on human liver cancer cells (SMMC-7721). 
 
2.9 Evaluation of blank alginate microspheres for hepatic 
embolization in rabbits 
Black alginate microspheres of mean size 59.10 μm were injected into 
the hepatic artery of the rabbit and their passage along the vessel closely 
monitored by angiography. The microspheres were found to be lodged in the distal 
end of an arteriole. Before embolization, the liver arterial angiogram showed a 
normal image of the trunk and branch of the liver artery (Figure 24a). After 
embolization, the proximal end of the hepatic artery was enlarged, while the distal 
end was not visible due to vascular occlusion caused by the alginate microspheres 
(Figure 24b).  
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Figure 24   Angiograms of hepatic artery in rabbit: (a) before embolization; (b) 
after embolization. 
 
Histopathological examination of the liver tissue showed that the 
microspheres were still present in the hepatic arteriole after 24 h (Figure 25). The 
microspheres caused some inflammation around the arteriole, but no necrosis. The 
periodic angiography indicated that the alginate microspheres were excellent 
embolization agents, which displayed satisfactory temporary liver arterial 
embolization effects in the rabbit. 
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Figure 25  Histopathological section of liver tissue 24 h after injection of alginate 
microspheres (the arrow points to the microsphere in the hepatic 
arteriole). 
 
2.10 Summary of Part 2 of study 
Drug-loaded alginate microspheres could be produced using either ethyl 
acetate or isooctane as continuous phase. However, isooctane was preferred as it 
enabled better control of microsphere properties. The particle size, extent of 
aggregation and drug content of the microspheres were affected by the type of 
drug, surfactant and stirring speed employed. Reducing the stirring speed 
increased particle size, which in turn decreased the drug release rate. The latter 
effect was however small. Hence, the strategy of controlling release rate by 
particle size met with only limited success. 
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On the other hand, alginate microspheres have the advantage of 
bioadhesive and biodegradable properties. Although the integrity of alginate 
microspheres could be sustained for 60 min, their function as a 
chemoembolization agent was undermined by their rapid drug release.  
 
RESULTS AND DISCUSSION
Part 3: Development of composite PLGA-alginate 
microspheres as chemoembolization agents 
Alginate microspheres were found not ideal as the chemoembolization 
agent, primarily because of their rapid drug release. Additives, such as liposomes 
(Monshipouri and Rudolph, 1995), cellulose derivatives (Chan et al., 1997), 
chitosan (Murata et al., 1999) and poly-L-lysine (Chang et al., 1999) have been 
employed to modify drug release from alginate matrices. Each of these additives 
have their advantages, as well as limitations. Poly (lactic-co-glycolic acid) (PLGA) 
has attracted much attention due to its controllable degradation rate, proven 
biocompatibility and FDA approved for use as a polymer in implants. However, 
few studies have reported on alginate and PLGA as co-polymers for controlled 
drug delivery. It was postulated that composite microspheres consisting of PLGA 
particles entrapped in an alginate matrix could be developed to control drug 
release.  
3.1 Comparison of microspheres produced respectively from 
alginate, PLGA and their blend 
In this study, 3 types of microspheres were prepared and their properties 
were compared (Table 13). Preparation of the alginate or PLGA microspheres was 
based on the formation of a primary emulsion while that of PLGA-alginate 
microspheres involved a multiple emulsion. The latter enabled the formation of 
composite microspheres that were postulated to be a more effective 
chemoembolization agent. Using the emulsification method, all the formulations 
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produced a free-flowing powder composed of microspheres. Upon dispersing the 
powder in distilled water, relatively discrete and spherical microspheres were 
observed under the optical microscope. Unlike the other 2 types with 
homogeneous matrix, the composite microspheres (PAM) consisted of numerous 
tiny spheroids within (Figure 26). This observation showed that the liquid PLGA 
droplets were stable in the alginate solution and they gradually solidified to form 
spheroids within the cross-linked alginate matrix as the solvent was lost.  
 




Formula Production conditions 
Alginate Sodium alginate 1.5 g 
Norcantharidin 1.5 g 
Simple emulsion method with 
isooctane as the continuous phase, 
Tween 85 and Span 85 as the 
surfactant, CaCl2 as the crosslinking 
agent. 
PLGA PLGA 0.8 g 
Norcantharidin 0.2 g 
Solvent-evaporation method with 
ethyl acetate as the solvent, PVA as 
the surfactant 
PLGA-alginate PLGA 0.8 g 
Norcantharidin 0.2 g 
Sodium alginate 1.5 g 
Multiple emulsion method cum 
crosslinking of sodium alginate with 
ethyl acetate as solvent for PLGA, 
Tween 85 and Span 85 as the 





Figure 26   Morphology of PLGA-alginate microspheres observed under the (a) 
optical microscope and (b) scanning electron microscope. 
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All the batches of microspheres showed unimodal size distribution 
(Figure 27). More than 75 % of the microspheres of each type had particle size 
within 30-100 μm. The liver is supported by arterioles that branch from the 
hepatic artery. It was reported that the diameters of normal arterioles (20-30 m) 
were such smaller than those of the Walker 256 carcinoma found in the liver 
(25-75 m) (Meade et al., 1987). Injection of microspheres in the latter size range 
would lead to their capture in the carcinoma arterioles to provide the desired 
embolization effect. On the other hand, microspheres much larger than 100 m 
would be trapped in the primary vessels that branch into smaller ones. This is 
undesirable as it may obstruct the supply of nutrients and oxygen to most parts of 
the organ, which will lead to liver failure. Hence, it is important to employ 
microspheres of appropriate size which was reported to be around 100 μm (Gupta 
and Hung, 1989). Ideally, the microspheres administered are of varying sizes to 
produce more effective embolization (Li, et al., 2004). In this study, all the batches 
of microspheres conformed to the afore-mentioned size requirement. 
 




All the 3 types of microspheres had a relatively low content of 
norcantharidin. This could be aptly accounted by the high solubility of 
norcantharidin in water (9.3 g/100 ml at 20oC), resulting in considerable drug loss 
to the aqueous medium during emulsification and washing. The drug content of 
the microspheres decreased in the following order: PLGA-alginate (4.25%) > 
PLGA (3.92%) > Alginate (2.56%). The low drug content for alginate 
microspheres was due to high drug loss from the porous alginate matrix during 
washing of the microspheres when they were prepared. In contrast, the highest 
drug content was obtained for the composite microspheres as there was hindrance 
to drug loss from the PLGA microspheroids entrapped in the surrounding alginate 
matrix. 
3.2 Influence of formulation factors on the production of 
PLGA-alginate microspheres 
3.2.1 Effects of amount of sodium alginate and proportion of PLGA to 
alginate
In this study, microspheres were prepared with fixed amounts of PLGA 
and norcantharidin, but varying amounts of sodium alginate (Table 14). Results 
showed that NPAM prepared using a higher alginate concentration had higher 
norcantharidin content. The encapsulation efficiency increased from 10.8 % to 
33.0 % when alginate concentration increased from 1 % to 3 %. It was reasonable 
to conclude that a higher proportion of encapsulating polymer had decreased drug 
loss during emulsification and washing. 
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Alginate 3 43.2±3.7 2.6±0.4 90.2±2.2 0.75 
PLGA - 54.7±4.6 3.9±0.7 18.9±5.3 0.88 
PLGA:alginate      
1:1 1.0 37.0±5.2 2.5±1.8 17.4±5.5 0.94 
1:1.5 1.5 41.4±6.0 3.5±0.7 15.7±9.8 0.94 
1:2 2.0 42.9±6.8 3.6±1.4 14.0±7.6 0.94 
1:2.5 2.5 44.3±5.9 3.9±2.0 13.9±5.6 0.96 
1:3 3.0 46.9±5.3 4.3±1.0 10.5±8.8 0.95 
 
3.2.2 Effect of organic solvents  
The PLGA-alginate microspheres were prepared by first dissolving 
PLGA in an organic solvent. Dichloromethane (DCM) is commonly used to 
dissolve PLGA and residual amount of the solvent may remain in the 
microspheres produced. This has caused some concerns as dichloromethane was 
reported to be selectively carcinogenic (ICH, 1995). It was felt that ethyl acetate 
(EA) might be a better substitute for dichloromethane as it was deemed safer and 
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could dissolve PLGA. However, it was reported that replacement of 
dichloromethane with ethyl acetate as an organic solvent reduced the 
encapsulation efficiency and increased the porous nature of the microspheres 
(Herrmann and Bodmeier, 1998). Hence, this study was undertaken to compare the 
effects between ethyl acetate and dichloromethane.  
A significant (p<0.05) increase in microparticles size was observed if the 
solvent was changed from dichloromethane to ethyl acetate (Table 15). The reason 
is perhaps due to the better miscibility of ethyl acetate with water. The solvent 
resided in polymeric microdroplets and caused the microspheres to soften and 
agglomeration. Results also showed significantly (p<0.05) higher drug content and 
encapsulation efficiency (p<0.05) for microspheres prepared with ethyl acetate 
compared with those prepared with dichloromethane. Based on these positive 
results, the microspheres were prepared with ethyl acetate for further study. 
 














PAM DCM 31.5±2.4 72.7±5.4 6.1±1.0 24.3±2.5 
PAM EA 34.6±3.3 75.1±4.7 7.4±0.8 29.6±1.2 
3.2.3 Effect of PVA  
By the conventional method of preparing PLGA microspheres, the 
polymer solution is dispersed in an aqueous medium. The addition of PVA is 
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necessary to enhance the stability of the dispersion and size of microspheres 
produced. It was reported that the addition of PVA led to the formation of 
relatively small particles with a narrow size distribution (Yang et al., 2001).  
The effect of PVA on the production of PLGA-alginate microspheres 
was investigated. For the preparation of the microspheres, PLGA solution was 
dispersed in the sodium alginate solution, with and without PVA. The properties 
of the microspheres obtained are shown in Table 16.  


















0 EA 34.6±3.3 75.1±4.7 7.4±0.8 29.60±1.2 
0.1 EA 29.7±4.2 52.2±5.3 7.1±1.2 28.5±2.2 
0.5 EA 36.2±3.8 45.8±6.1 6.5±0.9 26.2±1.0 
 
The mean particle size of the microspheres was significantly reduced by 
increasing the concentration of PVA (p<0.05). This showed that PVA also aided 
in the dispersion of sodium alginate solution in the secondary emulsion. However, 
the drug content and encapsulation efficiency also decreased, but to a smaller 
extent. Since PVA did not offer any significant advantage and it was not included 
in subsequent formulations. 
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3.3 Study of the impact of selected formulation and process 
parameters by orthogonal design 
It is important to identify and control the critical formulation and process 
conditions to produce microspheres with the desired properties. Optimization by 
using an experimental design is an efficient and systematic method to shorten the 
experimental time in technological process development. Orthogonal design is 
useful for optimizing multivariable processes (Heng et al., 2000). For the present 
work, a study was carried out to evaluate the influence of four independent 
variables, i.e. concentration of PLGA in ethyl acetate (A), volume of ethyl acetate 
(B), stirring speed for dispersion of ethyl acetate-PLGA in sodium alginate 
solution (C) and its emulsification time (D), with the aim of optimizing conditions 
for producing microspheres with high yield and encapsulation efficiency, suitable 
particle size and lower burst effect. 
According to the orthogonal design, 9 combinations of operation 
conditions were employed to produce the microspheres in triplicated batches. The 
yield, particle size, encapsulation efficiency and burst effect of the various batches 




Table 17   Properties of microspheres produced by different sets of conditions 
according to the orthogonal design  
Expt No. 
Yield 








1  49.3 ± 0.1  81.5 ± 4.3  50.4 ± 0.5  18.1 ± 2.7  
2  58.4 ± 0.1  55.4 ± 4.7  59.9 ± 1.9  15.8 ± 1.7  
3  57.6 ± 0.2 34.4 ± 7.4  23.9 ± 0.8  12.8 ± 1.4  
4  71.4 ± 0.1  75.2 ± 4.4  30.5 ± 1.6  16.7 ± 2.7  
5  59.1 ± 0.4  52.7 ± 4.1  59.6 ± 0.6  13.8 ± 1.1  
6  33.3 ± 0.8  46.9 ± 5.4  36.1 ± 4.6  7.4 ± 1.2  
7  71.1 ± 0.1  55.1 ± 3.6  14.7 ± 4.3  10.5 ± 1.3  
8  26.3 ± 0.5  77.1 ± 1.6  25.1 ± 6.5  9.6 ± 0.9  




















Kx,1 55.1 63.9 36.3 52.3 
Kx,2 54.6 47.9 59.4 54.3 
Kx,3 48.6 46.5 62.6 51.8 
1, yield (%) 
Rx 6.4 17.5 26.3 2.5 
Kx,1 57.1 70.6 68.5 57.3 
Kx,2 58.3 61.7 56.1 52.5 
Kx,3 56.6 39.6 47.4 62.2 
2. particle size 
(m) 
Rx 1.7 31.0 21.1 9.7 
Kx,1 44.7 31.9 37.2 48.4 
Kx,2 42.1 48.2 41.9 36.9 
Kx,3 25.0 31.8 32.7 26.5 
3. encapsulation 
efficiency (%) 
Rx 19.7 16.4 9.1 22.0 
Kx,1 15.6 15.08 11.7 12.9 
Kx,2 12.6 13.06 13.1 11.3 
Kx,3 8.9 8.99 12.4 13.0 
4. burst effect 
(%) 





3.3.1 Impact on yield 
As indicated by the R values, the four factors affected the yield to 
different extents: C>B>A>D (Figure 28). Stirring speed and volume of ethyl 
acetate had a marked effect on the yield while the concentration of PLGA and 
emulsification time had much less effect. The Kx,y values indicated that the yield 
increased by 23.15% when stirring speed increased from 600 rpm to 800 rpm. 
Further increase in stirring speed to 1000 rpm resulted in smaller increase in yield 
(3.15%). In contrast, the yield decreased with increasing volume of ethyl acetate. 
The decrease in yield was large (16.01%) when the volume of ethyl acetate was 
increased from 1 ml to 2 ml. Further increase in volume to 5 ml decreased the 
yield to a markedly lower extent (1.45%). The results showed that the optimal set 
of conditions to obtain microspheres with high yield consisted of C3B1A1D2. 
 
 




3.3.2 Impact on particle size 
As indicated by the R2 values, the 4 factors affected the microsphere size 
in the following order: B>C>D>A (Figure 29). The volume of ethyl acetate 
(R2=30.96) showed a markedly greater influence than the concentration of PLGA 
(R2=1.65). 
 
Figure 29 Effects of the four factors (A, B, C, D) on particle size of PLGA-alginate 
microspheres. 
The microsphere size decreased linearly with increasing stirring speed 
(r2=0.989). A similar trend was observed for the volume of ethyl acetate. This 
trend can be explained by more effective emulsification at higher stirring speed, 
thus producing smaller droplets of sodium alginate solution that led to the 
formation of smaller microspheres. The influence of PLGA concentration and 
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emulsification time was however more complicated as indicated by the non-linear 
relationship between the Kx,y values and the corresponding levels of each of these 
2 factors. All the batches of microspheres obtained had particle sizes ranging from 
34 - 82 m. The results showed that the optimal set of conditions to obtain 
microspheres closer to the desired particle size of around 100 m consisted of 
B1C1D3A2. 
3.3.3 Impact on encapsulation efficiency 
As indicated by the R3 values, the 4 factors affected the encapsulation 
efficiency in the following order: D>A>B>C (Figure 30). The emulsification time 
showed the greatest influence among these factors (R=21.96). The encapsulation 
efficiency decreased linearly with increasing emulsification time (r2=0.952). 
Clearly, there was greater opportunity for drug loss to the surrounding medium 
with prolonged time. A similar trend was observed for the PLGA concentration. 
The mechanism of this effect was however less clear and it might be related to the 
loss of norcantharidin during the dispersion process. The influences of stirring 
speed and volume of ethyl acetate were however more complicated as indicated by 
the non-linear relationship between the K values and the corresponding levels of 
each of these 2 factors. The results showed that the optimal set of conditions to 




Figure 30 Effects of the four factors (A, B, C, D) on encapsulation efficiency of 
PLGA-alginate microspheres. 
3.3.4 Impact on burst effect 
Burst effect is commonly observed in the release profiles of various 
drugs from microspheres (Shukla and Price, 1989). The initial faster release of 
norcantharidin from PAM in earlier dissolution studies was observed (Table 14). It 
was markedly less compared to that of alginate microspheres. Burst effect should 
be minimized as it will reduce the efficiency of the targeted delivery preparation in
vivo. 
Results showed that the 4 factors affected the burst effect in the 
following order: A>B>D>C (Figure 31). The burst effect decreased linearly with 
increasing PLGA concentration (r2=0.994). A similar trend was observed for the 
volume of ethyl acetate (r2=0.992). Stirring speed and emulsification time did not 
have any marked effect on the burst effect (R4 values were 1.40 and 1.75 
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respectively). The optimal set of conditions to produce microspheres with low 
burst effect consisted of A3B3D2C1. 
 
 
Figure 31 Effects of the four factors (A, B, C, D) on burst effect of PLGA-alginate 
microspheres. 
3.3.5 Derivation of optimal production conditions by multiple 
regression analysis 
Multiple regression analysis was employed to construct models to 
quantitate the contribution of the different factors to any desired outcome. The 
relationships among the factors and the 4 properties (yield, particle size, efficiency 







By integrating these models, the optimal combination of the factors and 
levels was found to be as A2B1C3D1. Therefore, the optimum production 
conditions consisted of: 1 ml of ethyl acetate containing 0.25 g of PLGA and 0.25 
g of norcantharidin dispersed in 50 g of aqueous solution containing 0.75 g of 
sodium alginate, at a stirring speed of 1000 rpm for 2.5 min. Using this set of 
conditions, microspheres were produced. 
The microspheres reproducibility was good as no significant differences 
were found in yield, particle size, encapsulation efficiency and burst effect among 
the three batches of the same microspheres produced. The mean size of the 
microspheres was 69.6 ± 5.0 m with norcantharidin content and encapsulation 
efficiency at 11.7 ± 1.0 % and 58.3 ± 2.1 % respectively. 
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3.4 In vitro drug release from PLGA-alginate microspheres 
Norcantharidin-loaded PAM preparation with intermediate alginate 
concentration of 3 % w/w was selected for comparison with the alginate 
microspheres and PLGA microspheres (Figure 32). Drug release from the alginate 
microspheres was comparatively very fast, with more than 90 % norcantharidin 
released within an hour of dissolution test. In practice, such microspheres are 
unlikely to be able to maintain any sustained release for a constant drug blood 
level. In contrast, drug release from the PLGA microspheres was extremely slow, 
with only 30 % norcantharidin released after 24 h. The release appeared to have 
leveled off after the first few hours of release. As a result, they may not be able to 
provide an adequate drug level. The composite NPAM showed intermediate drug 
release. After an initial rapid release phase (burst effect), a zero-order release 
profile (r=0.949) was observed. The moderate release rate constant would be able 
to provide an adequate drug level for a much longer period of time than the 
alginate microspheres. 
As suggested by previous reports (Loewe et al., 2002), chemo- 
embolization may cause side-effects related to the drug in response to burst effect. 
Hence, burst effect should be made as small as possible. The burst effect is usually 
brought about by the presence of free drug on the surface or drug near to the 
surface of microspheres. The drug at the surface is more readily released as it is 
more accessible to the dissolution medium. NPAM showed much reduced burst 
effect than the alginate and PLGA microspheres. Incorporating norcantharidin in 
PLGA, which was in turn entrapped as spheroids in the alginate matrix 
significantly reduced the burst effect (Table 14). The percentage of drug released 
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due to burst effect decreased with higher proportion of alginate in the composite 
microspheres. However, as zero-order rate was achieved, it indicated that drug 
release was largely controlled by the PLGA spheroids entrapped in the alginate 
matrix. The latter had minimal influence on the release rate of norcantharidin. 
 
Figure 32 Release profiles of microspheres: alginate (), PLGA-alginate () and 
PLGA (). 
 
3.5 Degradation time of PLGA-alginate microspheres 
PLGA microspheres took more than 14 days to degrade in pH 7.4 
phosphate buffer solution. In contrast, alginate microspheres degraded relatively 
fast (2 h). The degradation time of PLGA-alginate microspheres was intermediate 
(4 days), indicating that the addition of PLGA helped to preserve the integrity of 
the alginate-based microspheres.  
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It was reported that PLGA microspheres took up to several months to 
break down in physiological fluids (Shive and Anderson, 1997). Thus, they will be 
best for long-term embolization. However, the major drawback for such strategy is 
that such long-term embolization causes the development of collateral vessels to 
bypass the occluded one. It was also reported that the embolization material 
should break down within several days to avoid foreign body reaction (Madoule, 
et al., 1984). Based on the above reasoning, the composite microspheres were 
thought to be more suitable than the alginate or PLGA microspheres as 
embolization agents. 
3.6 Growth inhibitory effect of norcantharidin-loaded 
PLGA-alginate microspheres on liver cancer cells 
Blank PLGA-alginate microspheres (BPAM) had minimal growth 
inhibitory effect on the liver cancer cells, indicating that alginate and PLGA did 
not exhibit any significant cytotoxicity (Figure 33). Cancer cells exposed to 5 
g/ml of NPAM for 24 h were significantly inhibited (GI=11.55%). The extent of 
growth inhibition increased linearly with increasing concentration of NPAM used 
(r=0.9640), indicating that the inhibitory effect was concentration-dependent. A 
similar trend was observed for exposure times of 48 and 72 h. The plots of growth 
inhibition versus NPAM concentration were compared (Figure 33). The slope the 
plot was found to increase from 17.27 for exposure time of 24 h to 25.7 % for 48 h 
and 38.3 % for 72 h respectively. This clearly showed that the growth inhibitory 
effect increased with exposure time. The microsphere concentrations needed to 
inhibit 50 % of the cancer cells (IC50 values) were 110.23, 70.59 and 35.52 g/ml 




Figure 33  Growth inhibitory effects of NPAM and BPAM on SMMC-7721 liver 
cells. 
 
At 5g/ml of NPAM, there was insignificant differences in growth 
inhibitory effects between exposure times of 24 and 48 h (Figure 33). However, an 
increase in exposure time increased the growth inhibitory effect of higher 
concentrations of NPAM. The slopes of the plots increased with increasing 
concentrations of NPAM, indicating that time effect increased with concentration. 
3.7 Summary of Part 3 of study 
PLGA-alginate microspheres with desired properties were successfully 
prepared by a double emulsification method. The size of the microspheres 
increased with the concentration of alginate employed. The composite 
microspheres showed a drug release rate that was intermediate between those of 




characterized by initial burst effect, followed by zero order release. The release 
rate was governed by the PLGA component, with the alginate matrix having 
minimal role. PLGA-alginate microspheres containing norcantharidin was 
effective in destroying the cancer cells used in this study. The growth inhibitory 
effect was concentration and time dependent. 
 
RESULTS AND DISCUSSION
Part 4: PK/PD and tissue distribution of PLGA-alginate 
microspheres
In this part of study, the pharmacokinetic characteristics and tissue 
distribution of norcantharidin after intravenous administration of 
norcantharidin-loaded PLGA-alginate microspheres in rats were investigated. The 
results were compared with those obtained after intravenous administration of 
norcantharidin solution. In addition, the embolization potential and therapeutic 
efficacy of the norcantharidin-loaded microspheres in rats bearing transplanted 
hepatoma were evaluated. 
4.1 Preparation and characterization of 125I-labelled bromine 
substituted norcantharidin  
125I-labelled bromine substituted norcantharidin (BSN) was prepared 
according to the procedure described in Section B11.2 and identified by thin-layer 
chromatography. There was only one spot with Rf value of 0.8~0.9. The melting 
point of the resultant BSN was 151~1530Cˈwhich corresponded to the value 
reported in the literature (Liu and Li, 1997).  
4.2 The pharmacokinetics of norcantharidin-loaded PLGA-alginate 
microspheres
PLGA-alginate microspheres consisting of 125I labeled BSN (INPAM) 
were prepared according to the operation conditions stated in Section B4.1. 
Equivalent doses of 125I labeled BSN and INPAM were administered by 
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intra-arterial route to rats. The plasma concentration of norcantharidin was 
determined at pre-determined intervals (Figure 34) and the pharmacokinetic 
parameters calculated (Table 19).  
 
Figure 34  Plasma concentration of norcantharidin after intravenous administration 
of equivalent doses of 125I-labeled BSN and INPAM 
 
Table 19   Pharmacokinetic parameters of norcantharidin following intravenous 
administration of 125I-labeled BSN and INPAM in rats (n=5) 
Parameters 125I-labeled BSN  INPAM 
AUC0-˄%hml-1˅ 15.87 16.44 
t1/2˄h˅ 8.35 21.00* 
CLtot (mlh-1) 10.47 6.30* 
Vd (L) 9.95 0.98* 
* p<0.05 vs. 125I-labeled BSN. 
 121
RESULTS AND DISCUSSION
It can be seen from Figure 34 that the plasma level of norcantharidin at 
each time point from 4 to 72 h was higher for the drug-loaded microspheres than 
the drug solution. The AUC0- of norcantharidin from the microspheres was larger 
by 0.57 %·h·ml-1 and the total body clearance much lower by 4.17 mlh-1. This 
implied that incorporation of norcantharidin into PLGA-alginate microspheres 
could significantly decrease the renal clearance rate and increase the retention time 
in the plasma compared with norcantharidin solution. 
4.3 Tissue distribution of norcantharidin from PLGA-alginate 
microspheres
As shown in Figure 35 and Figure 36, norcantharidin from both the 
solution and microspheres was found in larger amounts in tissues such as liver and 
tumour. The drug targeting and drug selective indices of microspheres are shown 
in Table 20. The drug selective indices were greater than one, indicating that the 
microspheres delivered a larger amount of norcantharidin to the liver and tumour 
than the solution (p<0.05). For tissue samples taken 72 h after microspheres’ 
administration, drug levels in the organs other than liver were hardly detectable.  
Table 20 Drug targeting and drug selective indices of PLGA-alginate 
microspheres 
 Tissues 1 h 24 h 48 h 72 h 
liver 6.12 23.03 20.61 76.06Drug targeting index 
tumor 7.06  33.00 70.36 70.20
liver 19.13 24.65 40.07 37.60Drug selective index 




          
 
Figure 35   Tissue distribution of norcantharidin after injecting drug in 
solution. 
          
 
 
Figure 36 Tissue distribution of norcantharidin after injecting with PLGA-alginate 




4.4 Therapeutic efficacy of norcantharidin-loaded PLGA-alginate 
microspheres on rats bearing transplanted hepatoma 
The rats with transplanted hepatoma were treated with the control 
(normal saline) and different test agents (norcantharidin solution, blank 
PLGA-alginate microspheres and norcantharidin-loaded PLGA-alginate 
microspheres). The amount of norcantharidin solution and norcantharidin-loaded 
PLGA-alginate microspheres administered contained equivalent doses of drug. 
Tumor size of rats administered with normal saline increased markedly after 7 
days. 8 out of 9 rats suffered from diffuse metastasis and 6 of them developed 




Figure 37  Tumor response to treatment with various agents. 
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Interestingly, the tumor size of rats treated with norcantharidin solution 
also increased despite a greater extent of necrosis. The earlier part of this study 
had shown that the norcantharidin solution destroyed liver cancer cells. The 
histopathological responses of the tumours to normal saline and the different test 





Figure 38  Histopathological characteristics of tumor: (a) extensive infarction and 











Figure 38 (cont’d) Histopathological characteristics of tumor: (c) mid-range 
infarction after treatment with norcantharidin solution; (d) slight 




The increase in tumour size in response to norcantharidin solution could 
be attributed to under dosing or instability of the drug in the rat. An increase in 
size, as oppose to an increase in the extent of necrosis of tumor, was also observed 
for BPAM, indicating that embolization alone was inadequate to prevent tumor 
growth. Among the test agents, only NPAM was able to prevent growth of the 
tumor as indicated by its GR value of 1.1, which is close to unity. In addition, 7 of 
the 9 rats treated with NPAM showed tumor necrosis that was significantly greater 
than that of the other groups (Table 21, p<0.005).  
Table 21 Effect of various treatments on necrosis of tumor 
Score  
Group n 
+  ++  +++  
1  Normal saline  (1.5 ml/kg) 9 8 1 0 
2  0.3 % w/v norcantharidin solution 
(1.5 ml/kg) 7 2 5 0 
3  BPAM (10 mg/kg) 8 2 5 1 
4  NPAM (10 mg/kg) 9 0 2 7 
+ : slight necrosis in fragmentis 
++ : mid-range necrosis, absence of nuclei from many cells with or without 
massive cytoplasmic damage 
+++ : severe necrosis, total loss of cytoplasm of the carcinoma cells 
 
The effects of the different test agents on the survival time of rats with 
transplanted hepatoma were also determined (Table 22). All the rats eventually 
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died of carcinomatous and bloody ascites. Compared with the control group 
treated with normal saline, these symptoms were observed at a much later date for 
the test groups. The control group was found to have the shortest survival time of 
13.7 days.  
Both BPAM and norcantharidin solution increased the survival time to 
comparable extents (p > 0.05). This showed that embolization played an equally 
important role as the presence of the drug for the treatment of hepatoma. Among 
the test agents, NPAM produced the longest survival time (p < 0.01), 
corresponding to survival rate of 126.8 % or a survival time of 31 days. In terms of 
survival rate, these microspheres were at least 6 times more effective than the 
norcantharidin solution and BPAM. 
 
Table 22 Effects of different test agents on the survival of rats with transplanted 
hepatoma 




1 Normal saline  (1.5 ml/kg) 6 13.67 ± 2.16 - 
2 0.3 % w/v norcantharidin solution 
(1.5 ml/kg) 
6 15.83 ± 2.04 15.80 
3 BPAM (10 mg/kg) 6 16.50 ± 3.02 20.70 




4.5 Summary of Part 4 of Study 
Norcantharidin-loaded composite microspheres were markedly more 
effective than norcantharidin solution and blank microspheres in preventing tumor 
growth and increasing survival time of rats transplanted with hepatoma. These 
novel microspheres demonstrated synergistic effect of chemotherapy and 
embolization that is promising for the treatment of liver cancer.  
CONCLUSIONS 
V. Conclusions  
This study investigated different strategies to develop controlled-release 
alginate-based microparticulate systems for oral delivery and chemoembolization. 
These strategies include: (1) liquid phase coating of alginate microspheres to 
develop an oral delivery system for controlled drug release and (2) using alginate 
and PLGA composite to develop microspheres that were appropriate for 
chemoembolization.  
The concept of liquid phase coating was successfully applied to the 
coating of alginate microspheres with PMMA. The coating mechanism involved 
two stages (Part 1). In the first stage, the polymer was dissolved in acetone and the 
resultant solution dispersed in liquid paraffin. In the second stage, the cores were 
first dispersed in a small volume of liquid paraffin before adding to the above 
coating emulsion. Introduction of alginate microspheres affected the stability of 
the coating emulsion, resulting in gradual coalescence of the droplets of PMMA 
solution. The evaporation of acetone increased the polymer concentration and 
viscosity of the PMMA droplets. Some of these droplets were attracted to the 
surface of alginate microspheres. The presence of viscous PMMA solution on the 
microsphere surface made the microspheres tacky as they tended to stick to one 
another when they collided during the coating process. The properties of coated 
microspheres were affected by emulsifier and stirring speed. Results showed that 
reducing stirring speed increased particle size and sustained the drug release rate. 
Results also showed that the surface characteristics, particle size and drug content 
were different when different drugs were employed. This suggested that the 
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properties of the drug used had affected the preparation process and final product. 
However, results showed that release rate was just slightly sustained because of 
particle size. The strategy of controlling release rate by affecting particle size can 
be difficult to achieve.  
The emulsification technique was explored to produce alginate 
microspheres with the desired properties for application as chemoembolization 
agents. Alginate microspheres containing paracetamol were successfully produced 
by the emulsification method using ethyl acetate as the continuous phase (Part 2). 
The formation of the microspheres was affected by the type and concentration of 
surfactant, as well as the stirring speed. Compared with microspheres prepared 
with isooctane, these microspheres from ethyl acetate were larger and showed 
slightly lower drug release rate. Alginate microspheres have the advantage of 
bioadhesive and biodegradable properties and can be used as injectable products. 
Although the integrity of alginate microspheres could be sustained for 60 min, 
their function as a chemoembolization agent is undermined by their rapid drug 
release.
The concept of composite microspheres was employed to modify drug 
release in chemoembolization. PLGA-alginate microspheres were produced by 
multiple emulsion technique with a crosslinking step for sodium alginate. The 
resultant microspheres were aggregates containing very small PLGA microspheres 
entrapped within the alginate matrix. In Part 3, composite PLGA-alginate 
microspheres in the desired size range were successfully prepared by a double 
emulsification method. The size of the microspheres increased with increasing 




release rate that was intermediate between those of alginate microspheres and 
PLGA microspheres. The release profile was characterized by initial small burst 
effect, followed by zero order release. The release rate was governed by the PLGA 
component, with the alginate matrix having minimal role. In Part 4, 
norcantharidin-loaded composite microspheres were found to be markedly more 
effective than either norcantharidin solution or blank microspheres in preventing 
tumor growth and increasing survival time of rats transplanted with hepatoma. 
These novel microspheres demonstrated synergistic effect of chemotherapy and 
embolization. Thus, this is promising mode of treatment for liver cancer. These 
novel microspheres demonstrated synergistic effect of chemotherapy and 
embolization that is promising for the treatment of liver cancer. 
The significance of this research project is summarized as follows: 
 The liquid phase coating technique developed in this project may 
offer an efficient method of coating small microspheres with 
markedly reduced drug loss and controlled drug release. 
 PAMS are novel controlled release systems for water-soluble drugs. 
It may provide a new technique to entrap peptides and protein drugs 
into nanoparticles for oral delivery.  
 Norcantharidin containing PAMS may be a good candidate for 
chemoembolization purpose. It combines the bioadhesive property of 
alginate and drug retarding property of PLGA.  
FUTURE STUDY 
VI. Proposed future study  
This study showed that a double emulsion-crosslinking technique could 
successfully produce composite PLGA-alginate microspheres where the PLGA 
existed as microspheroids within a crosslinked alginate matrix. Drug release from 
these composite microspheres was markedly more sustained than that of plain 
alginate microspheres. However, the drug encapsulation efficiency was still 
relatively low. Nevertheless, the results obtained are promising. In order to exploit 
this concept fully for the development of controlled release alginate-based delivery 
systems, further studies are needed in the following areas as listed below. 
(i) Influence of the size (nano to micro range), proportion and type of PLGA 
particles in the composite microspheres on drug release and 
encapsulation efficiency. 
(ii) Better methods to prevent drug loss during production process of the 
microspheres. 
(iii) Examination of the effects of sterilization by gamma-irradiation, or other 
sterilization methods, on the properties of the microspheres. 
(iv) More extensive animal studies are required to validate the use of 
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EFFECT OF ETHYL ACETATE AS A CONTINUOUS PHASE ON ALGINATE 
MICROSPHERES PREPARED BY EMULSIFICATION 
Liu X., Chan L.W., Heng P.W.S. * 
Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore 117543 
Tel: 65-68742930, Fax: 65-67752265, E-mail: phapaulh@nus.edu.sg 
INTRODUCTION
Alginic acid is a naturally occurring polysaccharide 
and soluble sodium alginate can be cross-linked 
with calcium cations to form an insoluble alginate. 
Due to this property, alginate products can be 
employed as controlled release devices for some 
drugs.1 Calcium alginate microspheres were 
commonly prepared by extrusion. An alternative 
method, based on emulsification, was developed 
for the production of alginate microspheres.2 In this 
method, isooctane was employed as the continuous 
phase as it is immiscible with water and easily 
removed from the microspheres produced. 
However, toxicological information of isooctane is 
limited. A permissible exposure level of below 300 
ppm for isooctane is recommended.3 In contrast, 
the toxicity of ethyl acetate is low and ethyl acetate 
has not been shown to be a human carcinogen and 
reproductive or developmental toxin. Ethyl acetate 
is a permitted direct food additive by FDA.4 The 
objective of this study was to investigate the 
feasibility of using ethyl acetate as a continuous 
phase to prepare alginate microspheres by the 
emulsification method. The influence of surfactants 
and stirring speed on the morphology and drug 
release profiles of the microspheres was also 
investigated. 
EXPERIMENTAL 
50 g of a 5% w/w sodium alginate (low viscosity, 
Sigma, USA) solution with 0.5 g of paracetamol 
were dispersed in 100 ml of ethyl acetate (EA) 
containing Tween 85. The amount of Tween 85 and 
the stirring speed employed were varied. At 5 min, 
80 g of 1% w/w calcium chloride solution were 
added and stirred for another 5 min. This was 
followed by further addition of 50 g of 15% w/w 
calcium chloride solution. The test mixture was 
stirred for another 5 min before the microspheres 
were collected by filtration and dried at 40°C in the 
oven. The morphology of the microspheres was 
studied using a light microscope (BHZ, Olympus, 
Japan). At least 100 microspheres of each batch 
were sized and the mean size calculated. The drug 
content was determined by ultrasonicating 100 mg 
of microspheres in 100 ml of distilled water and 
assaying the drug in the filtrate 
spectrophotometrically (UV 1201, Shimadzu, 
Japan) at 250 nm. The drug release profile was 
studied using dissolution test (USP paddle method) 
with 1000 ml of distilled water as the dissolution 
medium at 37°C. 
RESULTS AND DISCUSSION 
Characteristics of alginate microspheres 
Calcium alginate microspheres containing 
paracetamol were successfully formed using EA as 
the continuous phase. The morphology of the 
alginate microspheres is shown in Fig. 1. The dried 
microspheres appeared shrunken and showed 
significant indentations on their surfaces, indicating 
a matrix that was not rigid and deformed upon the 
loss of water content during drying. This 
phenomenon was also observed in the 
microspheres produced with isooctane. The 
alginate microspheres were generally discrete, 
spherical and larger than those produced with 
isooctane. 
   
Figure 1. Photographs of alginate microspheres at 
different stages of the production process (a: after cross-
linking with calcium chloride; b: after filtration; c: after 
drying). 
Effect of surfactant 
Generally, the surfactants and HLB value play 
important roles in emulsification.5 Previous studies
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showed that a combination of hydrophilic and 
lipophilic surfactants with appropriate HLB value 
was critical for the formation of discrete and 
spherical alginate microspheres using isooctane.2
The formation of microspheres using EA was not 
possible without a surfactant or with Span 85 alone. 
However, Tween 85 alone was sufficient to aid in 
the dispersion of the aqueous sodium alginate 
phase as fine globules in EA. It was observed that 
the successful formation of microspheres was also 
dependent on the concentration of surfactant used. 
The yield was found to increase with increasing 
concentration of Tween 85. Drug content was 
generally low due to the solubility of paracetamol 
in EA. Hence, this aspect should be an important 
consideration in the selection of an appropriate 
continuous phase. Nonetheless, drug content was 
significantly higher when the concentration of 
Tween 85 was increased from 0.5% to 1.5% w/w. 
However, further increase in the surfactant 
concentration to 2.5 % w/w did not increase drug 
content significantly. Being surface active, Tween 
85 molecules would form a monolayer at the 
interface between the sodium alginate phase and 
EA. The results suggested that this monolayer of 
surfactant molecules reduced drug loss through 
partitioning into EA to a certain extent. On the 
other hand, high surfactant concentration was 
associated with greater solubilising effect which 
favored drug loss through the aqueous washings. 
The outcome was determined by the balance of 
these two opposing effects. 
Table 1 
Properties of microspheres obtained with different 
concentrations of Tween 85 at stirring speed of 600 
rpm  
Concentration
of Tween 85 






0.5 246±28 1.96 2.04 
1.5 231±17 2.65 2.23 
2.5 226±13 2.72 2.28 
Effect of stirring speed 
At the same concentration of Tween 85, the mean 
size of the microspheres increased with inceasing 
stirring speed before leveling off. At 1.5% w/w 
Tween 85 and low stirring speeds of 200 and 400 
rpm, more irregular microspheres formed. At 600 
and 800 rpm, most of the microspheres were discrete 
and spherical and their mean sizes were comparable. 
The minimum stirring speed required to produce 
microspheres of desired shape and size was 
dependent on the concentration of surfactant used. 
Drug release from alginate microspheres 
Alginate microspheres were produced using EA and 
isooctane and their in vitro drug release profiles were 
compared. For both types of microspheres, more than 
80 % of the drug was released within 30 min. Drug 
release from the microspheres produced with ethyl 
acetate was slightly lower. The mean size of the 
microspheres produced with isooctane and EA were 
85.6 and 231 μm respectively. Hence, the slower 
release was most likely due to the bigger particle size 

















Figure 2. Effect of stirring speed on the mean size of 




















Figure 3. Drug release profiles of alginate microspheres 
prepared with different solvents. 
Further studies showed that drug release was slower 
for bigger microspheres (Figure 3). Since drug release 
was relatively fast, the alginate microspheres were not 
appropriate as sustained release delivery systems but 
they are good drug carriers. 
CONCLUSION 
Alginate microspheres containing paracetamol 
were successfully produced by the emulsification 
method using EA as the continuous phase. The 
formation of the microspheres was affected by the 
type and concentration of surfactant, as well as the 
stirring speed. Compared with those prepared with 
isooctane, these microspheres were larger and 
showed slightly lower release rate.  
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Feasibility Study of a Double Encapsulation Technique to Produce Coated Alginate 
Microspheres for Prolonged Drug Release 
X. Liu, L. W. Chan, and P. W. Heng
National University of Singapore 
Purpose. To explore Eudrugit® coating of alginate microspheres by a double encapsulation technique to produce prolonged 
release of a hydrophilic drug for oral administration.  Methods. Calcium alginate cores containing paracetamol were 
prepared using an emulsification method. Eudrugit® (RS100 and S100) was dissolved in acetone and emulsified in liquid 
paraffin. A dispersion of the cores in liquid paraffin was added to the emulsion and stirred continuously for 3 h. The coated 
alginate microspheres formed harvested and dried in a vacuum oven. The secondary encapsulation process was monitored by 
microscopic examination to elucidate the coating mechanism. The mine size and drug encapsulation efficiency of the coated 
microspheres were determined their drug release kinetics in simulated gastric (SGF) and intestinal (SIF) fluids were 
investigated.  Results. The alginate cores were mostly discrete, with a mean size of 85.6 μ. Encapsulation of the alginate 
cores occurred by agglomeration of the Eudragit® droplets, resulting in entrapment of multiple alginate cores within a 
Eudragit® RS100 and S100 were 807.4 μ and 546.7 μ respectively. Their high drug encapsulation efficiencies of 92.2 % and 
84.0 % showed little loss of drug during the secondary encapsulation process. Eudragit® RS100-coated microspheres showed 
markedly retarded drug release in both SGF and SIF. Drug release from the Eudragit® S100-coated microspheres in SGF was 
even slower but as rapid as that of the uncoated microspheres in SIF. The two types of coated microspheres released the drug 
by different mechanisms, which will be further discussed. Conclusions. Alginate microspheres were successfully coated 
using a double encapsulation technique with high drug encapsulation efficiency. The drug release kinetics of the coated 




column (column clearance) was varied. The MFR values at different column clearance 
were obtained for the Precision coater and Wurster coater. 
[Results and Discussion] For both coaters, the MFR increased, reached a peak, then 
decreased with increasing column clearance. However, MFR in the Precision coater was 
relatively lower and showed a greater range than that in the Wurster coater. This
indicated that the impact of the column clearance on the MFR was greater in the 
Precision coater than in the Wurster coater.  
[Conclusions] Column clearance has a greater influence on the MFR of pellets in the 
Precision coater than the Wurster coater. The column clearance should be appropriately 
adjusted to ensure proper flow of pellets during coating. 
R-15
Liquid Phase Coating to Sustained Drug Release from Alginate Microspheres 
Liu Xiaohua, L. W. Chan, P. W. S. Heng 
Department of Pharmacy, Faculty of Science, National University of Singapore, Level 4, Block S4, 
18 Science Drive 4, Singapore 117543 
[Objective] To explore a liquid phase coating technique to prepare Eudragit-coated 
alginate microspheres for sustained drug release.  
[Methods] Alginate cores containing paracetamol were prepared using an emulsification 
method. The cores were then coated at different core:coat ratios in an emulsion of coating 
polymers. Paracetamol was the model drug used. The morphology, drug loss during 
coating and dissolution profiles of microspheres were determined. Dissolution test was 
carried out using the paddle method at a stirring speed of 50 rpm at 37°C in simulated 
gastric (SGF) and intestinal (SIF) fluids.  
[Results] The coated microspheres consisted of agglomerates that were generally 
spherical in shape, with mean size ranging from 354 to 807 microns. The release of 
paracetamol from coated microspheres in SGF and SIF were retarded. Release rates of 
Eudragit RS100-coated microspheres were comparable. In contrast, drug release from 
Eudragit S100-coated microspheres was significantly faster in SIF than in SGF. It was 
also found that drug release decreased with increasing core:coat ratio. The mechanism of 
drug release from microspheres coated with different types of Eudragit and the gradual 
evolution of release kinetics with core:coat ratio will be further discussed.  
[Conclusion] Alginate microspheres were successfully coated using a liquid phase 
coating technique. The coated microspheres showed little drug loss during coating and 
significantly retarded drug release in in vitro dissolution test. The novel coating technique 
is useful for development of controlled delivery systems.   
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DEVELOPMENT OF A NOVEL CHEMOEMBOLIZATION AGENT  
FROM ALGINATE AND PLGA 
Xiaohua Liu1, Lai Wah Chan1, Qi Li2, Paul Wan Sia Heng1
1Department of Pharmacy, National University of Singapore, Singapore 
2Putuo Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China 
E-mail: phaclw@nus.edu.sg
Keywords: ALGINATE; PLGA; MICROSPHERES; CHEMOEMBOLIZATION; NORCANTHARIDIN. 
INTRODUCTION 
Chemoembolization is an effective method to treat liver 
cancer1. It combines two palliative approaches, arterial 
chemotherapy and local tumor ischemia, thus providing 
greater local concentration and controlled delivery of 
drug to the target tissue. This results in synergistic effect 
of embolization and reduced systemic side-effects. In 
chemoembolization, drug may be administered 
sequentially or concurrently with the embolization agent. 
Ideally, a chemoembolization formulation of an 
anticancer drug should have minimal burst effects and 
release the appropriate amount of drug to the tumor site 
for a prolonged period of time. To date, not many types 
of embolization agents have been studied. Among these, 
absorbable gelatin powder (Gelfoam®) and degradable 
starch microspheres (Spherex®) are most commonly used. 
In recent years, microspheres composed of 
polyvinylalcohol, zein, serum albumin, ethylcellulose, 
chitosan, ethylene-vinyl acetate and collagen have been 
developed for embolization2. None of the above 
embolization agents is ideal as each has its limitations. 
This has led to the on-going search for alternatives as 
embolization agent. 
Norcantharidin has been found in clinical studies to be 
effective against primacy liver cancer3. In this study, poly 
(lactic-co-glycolic) acid (PLGA)-alginate microspheres 
were developed to control the release of norcantharidin. 
The potential use of these microspheres for 
chemoembolization in the treatment of hepatoma in rats 
was explored. These microspheres were postulated to 
have two advantages, bioadhesiveness of alginate and 
slowly degrading PLGA, which make their combination 
excellent for chemoembolization. 
EXPERIMENTAL METHODS 
PLGA-alginate microspheres (PAMS) were prepared by 
using the multiple emulsion technique and involving 
crosslinking sodium alginate with Ca2+. Ethyl acetate 
containing PLGA and norcantharidin were dispersed in 
sodium alginate solution with stirring. The primary 
emulsion thus obtained was dispersed in isooctane. 
Calcium chloride solution was then added for cross-
linking. The microspheres formed were collected by 
filtration and dried in an oven at 40 oC. Alginate and 
PLGA microspheres were also prepared by a simple 
emulsification method for comparison with PAMS. 
The microspheres were examined using light (Olympus, 
BH2, Japan) and scanning electron (Jeol, JSM-5800, 
Japan) microscopes. The mean size of the microspheres 
was determined from at least 200 particles. 
The drug content of the microspheres was determined by 
ultrasonicating a known amount of microspheres in a 
specific volume of solvent. The drug was assayed 
spectrophotometrically at 211 nm using HPLC with a 
Thermo Hypersil C18 column (3 μ, 2.9 mm h 150 mm) 
and mobile phase of methanol and water (15:85), 
adjusted to pH 3 with phosphoric acid.  
Drug release from the microspheres was determined. An 
accurately weighed amount of microspheres was 
introduced into a flask containing 250 ml of USP 
phosphate buffer pH 7.4 and agitated in a shaker water 
bath at 37 oC. Aliquot samples were withdrawn at 
specific time intervals and replaced with an equal volume 
of buffer. The samples were assayed by HPLC as 
previously described. 
An animal model was used to evaluate the therapeutic 
effects of the microspheres. Twenty-four male Sprague-
Dawley rats (200-250 g) with transplanted hepatoma 
were divided equally into 4 groups, administered with 
normal saline (1.5 ml/kg), 0.3 % w/v norcantharidin 
solution (1.5 ml/kg), blank PAMS (10 mg/kg) and 
norcantharidin-loaded PAMS (10 mg/kg). The sterile 
samples were injected into the hepatic artery and the 
survival time of the rats determined. The therapeutic 
efficacy was indicated by the survival rate (SR), which 
was calculated as follows: 
SR = (STtest – STcontrol)h100 / STcontrol  
where STtest was the survival time for the test agent and 
STcontrol was the survival time for normal saline. 
RESULTS AND DISCUSSION 
Norcantharidin-loaded PAMS were successfully prepared 
by double emulsification. The microspheres obtained 
were generally discrete and spherical when dispersed in 
distilled water. The mean size of the microspheres was 
46.9±5.3 μm. Light microscopy showed very small 
PLGA microparticles containing norcantharidin (<10 μm) 
embedded in the microspheres (Figure 1A). SEM showed 
microspheres with rough surfaces due to the 
microparticles adhering onto the microsphere surface. 
Micropores and cracks were also found on the 
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microsphere surface. These features were most probably 
due to the evaporation of ethyl acetate through the 
alginate matrix during emulsification and drying.  
                      
                    A                                                B 
Figure 1: Morphology of microspheres: (A) PAMS dispersed in 
distilled water and (B) Dried PAMS. 
The microspheres had a relatively low content of 
norcantharidin (4.3 % w/w). However, the drug content 
was higher than that using only alginate (2.6 % w/w) or 
PLGA (3.9 % w/w) for microencapsulation, indicating 
that drug loss was decreased in the modified 
emulsification method. The low drug content could be 
aptly accounted by the high solubility of norcantharidin 
in water (9.3 g/100 ml at 20 oC), resulting in considerable 
drug lost to the aqueous medium during emulsification 
and washing. Nevertheless, norcantharidin is very potent, 
needing only small quantity for therapeutic activity and 
the final dose can be adjusted by varying the amount of 
microspheres used. 
Figure 2: Release profiles of alginate (), PAMS () and PLGA () 
microspheres.
The release profiles of norcantharidin from the 3 different 
types of microspheres are shown in Figure 2. Drug 
release from alginate microspheres was generally faster, 
with more than 90 % drug released after 1 h. On the 
contrary, drug release from PLGA microspheres was very 
slow, with only 36 % drug released after 24 h. PAMS 
showed intermediate drug release rate, with 11 % drug 
released after 1 h and 82 % drug released after 24 h. 
After an initial rapid release phase, PAMS released the 
drug at a relatively constant and moderately slow rate. 
According to literature report, burst effect should be 
avoided in chemoembolization as it may cause side 
effects4. In addition, the rate of drug release should not be 
too slow or too fast. In view of these criteria, PAMS was 
more suitable than alginate and PLGA microspheres for 
chemoembolization. The bioadhesive property of alginate 
would further contribute to the advantage of PAMS over 
PLGA microspheres. 
The effect of PAMS on the survival time of rats with 
transplanted hepatoma was determined (Table 1). All the 
rats eventually died of carcinomatous and bloody ascites. 
Compared with the control group treated with normal 
saline, these symptoms were observed much later in the 
test groups. The control group was found to have the 
shortest survival time of 13.67 days. Both blank PAMS 
and norcantharidin solution increased the survival time to 
comparable extents (p > 0.05). This showed that 
embolization played an equally important role as the drug 
in the treatment of hepatoma. Among the test agents, 
norcantharidin-loaded PAMS showed the longest 
survival time (p < 0.01), with survival rate of 126.77 %. 
In terms of survival rate, these microspheres were at least 
6 times more effective than the norcantharidin solution 
and blank PAMS. 
Table 1 Effects of microspheres on the survival of rats with 
transplanted hepatoma




Normal saline 6 13.67 ± 2.16 - 
0.3%w/v norcantharidin 
solution
6 15.83 ± 2.04 15.80 
Blank PAMS 6 16.50 ± 3.02 20.70 
Norcantharidin-loaded 
PAMS 
6 31.00 ± 3.85 126.77 
CONCLUSION 
A novel embolization agent, in the form of PLGA-
alginate microspheres, was successfully developed using 
a double emulsification method. Incorporation of drug in 
the primary emulsion consisting of PLGA significantly 
reduced drug loss and burst effect. Drug release rate of 
PLGA-alginate microspheres was intermediate between 
alginate and PLGA microspheres. In addition, they 
markedly increased the survival time of rats with 
transplanted hepatoma. Hence, the norcantharidin-loaded 
PLGA-alginate microspheres developed in this study are 
potentially useful as a chemoembolization agent in the 
treatment of liver cancer. 
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DEVELOPMENT OF PLGA-ALGINATE COMPOSITE MULTIPARTICULATE SYSTEM 
X. Liu, L. Chan, P. Heng
Pharmacy, National University of Singapore 
Purpose.  
This study aimed to develop a novel controlled-release multiparticulate system based on alginate and PLGA. 
Methods.  
Norcantharidin loaded PLGA-alginate microspheres (namely, NPAM) were produced by an emulsion-crosslinking technique. 
Four independent factors were studied using an orthogonal design with three levels for each factor. Physical properties such 
as morphology and size, characteristics of drug release and rate of degradation in vitro of the microspheres produced were 
determined. 
Results.  
The concentration and volume of PLGA were identified as more important among the four factors and should be at optimal 
level to produce good quality NPAM. The technique for producing the optimal NPAM microspheres was reproducible. The 
microspheres obtained were generally discrete and spherical when dispersed in distilled water. The mean size of the 
microspheres was 46.9¡À5.3 μm. Light microscopy showed very small PLGA microparticles containing norcantharidin (<10 
μm) embedded in the microspheres. SEM showed microspheres with rough surfaces due to the microparticles adhering onto 
the microsphere surface. Micropores and cracks were also found on the microsphere surface. The microspheres had a 
relatively low content of norcantharidin. However, the drug content was higher in NPAM than microspheres prepared with 
only alginate or PLGA. NPAM showed intermediate drug release rate compared with alginate microspheres and PLGA 
microspheres. After an initial rapid release phase, NPAM released the drug at a relatively constant and moderately slow rate. 
The release of norcantharidin from NPMA was controlled by the dissolution and diffusion of the drug from the PLGA matrix 
and alginate gel. 
Conclusion.  
A novel PLGA-alginate composite multiparticulate system was successfully developed. Incorporation of drug in the primary 
emulsion reduced drug loss and burst effect. PLGA-alginate microspheres showed their potential to be used for controlled-
release delivery of hydrophilic drugs, such as peptide and protein drugs. 
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Abstract
Chemoembolization has been found to be a potentially effective method of treating certain types of cancer. It involves arterial embolization of a
tumor, in combination with simultaneous or subsequent local delivery of chemotherapeutic agents. In this study, PLGA-alginate microspheres were
evaluated for their potential application in chemoembolization. Norcantharidin, which possesses anti-tumor properties, was used to investigate the
application of drug-containing microspheres for chemoembolization. The release profiles of alginate, PLGA and PLGA-alginate microspheres were
markedly different in phosphate buffered saline, with the composite microspheres showing the most appropriate release rate for chemoembolization.
Burst effect decreased while particle size increased with increasing proportion of alginate in the PLGA-alginate microspheres. PLGA-alginate
microspheres containing norcantharidin were effective in destroying the cancer cells used in this study. The growth inhibitory effect was
concentration and time dependent. Thesemicrospheres also exhibited excellent embolization and therapeutic effects on rats with transplanted tumors.
© 2006 Elsevier B.V. All rights reserved.
Keywords: Alginate; PLGA; Microspheres; Chemoembolization; Norcantharidin
1. Introduction
Targeted delivery of an anti-cancer drug to a tumor via arterial
chemoembolization is attracting increasing attention. It has been
found to be more effective than chemotherapy alone in the
treatment of cancer. Besides enabling a greater local concentration
of drug in the target tissue, it causes hypoxia of the tumor by
blocking its blood supply [1,2]. Systemic side-effects are also
reduced due to restricted blood circulation and localized
deposition of the drug. Chemoembolization is currently employed
for treating malignant hepatic tumors.
The chemoembolization procedure typically involves sequen-
tial or concurrent injection of drug and embolization agent [3].
Several materials, both natural and synthetic in origin, had been
used for embolization. Examples used included absorbable
gelatin powder (Gelform®) and gelatin sponge particles
suspended in a liquid medium that might or might not contain
the drug [4,5]. Chemoembolization had also been attempted using
microcapsules or microspheres. These were preferred as spherical
particles could be transported more distally than particles that
were irregular. More importantly, microcapsules or microspheres
produced more homogeneous and complete blood vessel
occlusion [6]. Degradable starch microspheres (DSM, Spherex®)
had been used as a chemoembolization agent. These are spherical
particles of about 45 μm in diameter, prepared by cross-linking
partly hydrolyzed potato starch with epichlorohydrin. DSM was
reported to cause temporary embolism after injection into a vessel,
before degrading within 40 min [7]. A slight spread of particle
sizes of the embolization agent is desirable for a more extensive
embolization. As commercially available DSM has a rather
narrow size distribution, its embolization effects are restricted [8].
Hence, it would be ideal if a mixture of drug-loaded particles of
greater varying sizes could be formulated to provide more
effective embolization, as well as localized drug delivery.
Alginate is a natural polysaccharide and has attracted much
attention as a matrix for drugs and immobilized cells since it is
non-toxic, biodegradable and can be cross-linked with polyvalent
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ions [9]. There had been few investigations on the use of alginates
for chemoembolization. This is perhaps due to the rapid drug
release rates of alginate microspheres [10]. On the other hand,
poly (lactic-co-glycolic) acid (PLGA) particles released drug very
slowly [11]. They also take a long time to degrade in the body,
which may induce the formation of lateral blood vessels to supply
the surrounding tissue and tumor [12,13]. Hence, in this study,
PLGAwas combined with alginate to form microspheres for use
in chemoembolization.
Norcantharidin is synthesized from cantharidin, which is an
active constituent obtained from the dried body of the Chinese
blister beetle (mylabris) [14]. The use of mylabris as a traditional
medicine in China can be traced back to over 2000 years. It was
found that norcantharidin possesses anti-tumor properties and has
the advantage of inducing the production of leucocytes [15].
Clinical studies showed that norcantharidin was effective against
primary liver cancer. However, the significant side-effect of
norcantharidin is irritation to the urinary organs, thereby limiting
its use [16]. Side-effects may be reduced by decreasing the dose.
Hence, the aforementioned limitation of norcantharidin may be
overcome by encapsulating the drug in PLGA-alginate micro-
spheres for chemoembolization at the target site as this mode of
treatment enables a smaller dose for therapeutic efficacy.
2. Materials and methods
2.1. Materials and animals
Sodium alginate (low viscosity, ISP, USA) and PLGA
(Resomer RG 502H, 50:50, Mw 10,000, Boehringer Ingelheim,
Germany) were used as the matrix polymer and norcantharidin
(Pingyuan Pharmaceutical, China) as the drug. Calcium chloride
dihydrate (Merck, Germany) was used as the cross-linking agent.
Tween 85 (Merck,Germany), Span 85 (Sigma-Aldrich, USA) and
polyvinyl alcohol (PVA, 15,000, Fluka Chemie, Switzerland)
were employed as emulsifiers. Ethyl acetate (Merck, Germany)
was used to dissolve PLGA and isooctane (Merck, Germany) was
used as the continuous phase of the emulsion. Tri-sodium
phosphate and hydrochloric acid (Merck, Germany) were used to
prepare the dissolutionmedia. RPMI 1640medium (Gibco, USA)
and fetal calf serum (Sijiqing, China) were used for cell culture.
Methyl thiazolyl tetrazolium (MTT, Sigma, USA) and dimethyl
sulfoxide (DMSO, Amresco, USA) were used in MTT assay.
Male Sprague-Dawley rats were purchased from Shanghai
Laboratory Animal Center (SLAC) for pharmacodynamic study.
All animals were housed in a temperature-controlled facility and
provided with standard diet and water ad libitum. All experiments
followed the recommendations of the local animal protection
legislation and approval (SYXK 2005-0008) was obtained from
the Ethics Committee of Shanghai University of Traditional
Chinese Medicine for conducting the animal study.
2.2. Preparation of PLGA-alginate, PLGA and alginate
microspheres
In the preparation of PLGA-alginate microspheres, 2 ml of
ethyl acetate containing 0.5 g of PLGA and 0.3 g of
norcantharidin was dispersed in 50 g of aqueous solution
containing sodium alginate using a mechanical stirrer (RW20
DZM, Ika-Werke, Germany) at 1000 rpm for 5 min. The
concentration of sodium alginate was varied from 1.0 to 3.0%
w/w (Table 1). The resultant primary emulsion was then
dispersed in 75 g of isooctane containing 2.54 g of Span 85 at
1000 rpm for 5 min. Five grams of aqueous solution containing
1.36 g of Tween 85 were added and stirring continued for
another 5 min. This was followed by the addition of 20 g of 15%
w/w calcium chloride solution and further stirring for 10 min.
Microspheres produced were collected by filtration in vacuo
and washed with 20 ml of distilled water thrice before drying in
an oven at 40±1 °C. Different concentrations of sodium
alginate were used. The norcantharidin-loaded microspheres
were referred to as NPAM.
PLGA microspheres were prepared by dispersing 2 ml of
ethyl acetate containing 0.8 g of PLGA and 0.2 g of norcan-
tharidin in 6 ml of aqueous solution containing 0.25% of PVA
using a vortex mixer (VPN-360, Gemmy, Taiwan) for 5 min.
The mixture was then added to 200 ml of aqueous solution
containing 0.25% of PVA stirred at 400 rpm for 24 h before
collection of PLGA microspheres by filtration. The micro-
spheres produced were dried in vacuo at room temperature
[17].
Alginate microspheres were prepared with 0.3 g of
norcantharidin in 50 g of 3% w/w sodium alginate solution
using the method for PLGA-alginate microspheres, without
PLGA-ethyl acetate [10].
The dried microspheres were passed through a sieve to
remove aggregates larger than 200 μm. Three batches were
prepared for each formulation and combined for evaluation. For
each formulation, blank microspheres without norcantharidin
were also prepared. Blank PLGA-alginate microspheres were
referred to as BPAM.
2.3. Optical microscopy and particle size measurement
Dried microspheres were dispersed in distilled water on a
glass slide. Images were captured using a video camera (CCD-
SMA-D2, Sony, Japan) connected to a light microscope (BX61,
Olympus, Japan) and analysed with the aid of an image
processing software (Micro Image V. 4.5, Media Cybernetics,
Table 1












(%, w/w) (μm) (%, w/w) (%)
Alginate 3.0 43.2±3.7 2.6±0.4 90.2±2.2
PLGA – 54.7±4.6 3.9±0.7 18.9±5.3
PLGA:alginate
1:1 1.0 37.0±5.2 2.5±1.8 17.4±5.5
1:1.5 1.5 41.4±6.0 3.5±0.7 15.7±9.8
1:2 2.0 42.9±6.8 3.6±1.4 14.0±7.6
1:2.5 2.5 44.3±5.9 3.9±2.0 13.9±5.6
1:3 3.0 46.9±5.3 4.3±1.0 10.5±8.8
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US). Particle size was expressed by the longest dimension of the
particle. The mean particle size and size distribution of each
formulation were obtained from at least 200 particles.
2.4. Scanning electron microscopy (SEM)
The microspheres were mounted on studs, gold splutter-
coated and their morphology examined under a scanning
electron microscopy (JEOL, JSM-5200, Japan).
2.5. Determination of drug content of NPAM
The drug content of norcantharidin-loaded PLGA-alginate
microspheres was determined by HPLC [18]. A Thermo
Hypersil C18 column (3 μ, 2.9 mm×150 mm) and mobile
phase composed of methanol:water (15:85), adjusted to pH 3
with phosphoric acid were employed. Norcantharidin was
assayed spectrophotometrically at 211 nm. The drug content
was expressed as the percentage of drug encapsulated with
respect to the dry weight of microspheres. The determinations
were carried out in triplicate for each formulation.
2.6. In vitro release study
250 g of microspheres were introduced into a flask
containing 250 ml of phosphate buffer solution (pH 7.4,
USP), agitated at 50 oscillations/min in a shaker water bath
(NTS1300D, Shengyi, China) at 37 °C. Two milliliter samples
were periodically withdrawn through a membrane filter and
assayed for drug using the HPLC method previously described.
The sample withdrawn was replaced with an equal volume of
phosphate buffer. The dissolution runs were triplicated for each
formulation and the results averaged.
2.7. Determination of disintegration time
The gross physical stability of the microspheres was
evaluated using the method described by Schwarz et al. [19].
Approximately 20 mg of microspheres were placed into a glass
vial, to which 10 ml of 50 mM phosphate buffer (pH 7.4) was
added. The vial was sealed and placed in an oven at 37 °C. The
height occupied by the microspheres in the vial was measured
at specified time intervals. The microspheres were deemed to
have disintegrated when no traces of microspheres were
detected.
2.8. In vitro study of growth inhibitory effect of NPAM on liver
cancer cells
Human liver cancer cell line SMMC-7721 (obtained from
Eastern Hepatobiliary Hospital, China) was grown in RPMI
1640 medium, supplemented with 10% fetal calf serum at
37 °C in 5% CO2 and 95% air. Cells from the exponential
phase of the culture were harvested and diluted to a cell
density of about 2×104 per ml. 100 μl of the cell suspension
was added to 180 μl of medium in each well of a 96-well
plate, incubated at 37 °C, 5% CO2 and 95% air for 1 day.
100 μl of normal saline consisting of different amounts of
NPAM was then added to the respective wells and incubated
for a specific period of time. The cells were then rinsed with
PBS before 20 μl of PBS consisting of 5 mg/ml of MTT was
added and incubated for 4 h. This was followed by the
addition of 150 μl of DMSO and the plate agitated on a plate
shaker for 10 min. The optical density (OD) of the contents in
each well was then measured at 570 nm using a bioassay
reader (BioRad, USA). Controls were conducted using normal
saline without NPAM. The incubation time of cells in normal
saline and NPAM were varied from 24 to 48 and 72 h,
respectively. The OD values reported were obtained from 3
sets of 5 determinations each. The growth inhibitory (GI)




where ODtest and ODcontrol are the mean OD values for
normal saline with and without NPAM, respectively.
Fig. 1. Morphology of PLGA-alginate (1:3) microspheres observed under the
(A) optical microscope and (B) scanning electron microscopy.
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2.9. In vivo study of therapeutic efficacy on rats with trans-
planted hepatoma
Sixty-four male Sprague-Dawley rats (200–250 g) were
transplanted with hepatoma (Walker 256 carcinoma cells) in
accordance with the technique previously described by Ling et al.
[20]. The rats were divided into four groups of 16.With the aid of a
binocular microscope (YZ-20T4, Suzhou Medical Device, China)
for laparotomy, a silastic microcatheter (ID 0.25 mm, OD 0.4 mm)
was retrogradely inserted into the gastroduodenal artery leading to
the hepatic artery. The 4 groups were administered with normal
saline, norcantharidin solution, BPAMandNPAM, respectively, by
injection through the microcatheter. Seven days after the injection,
six rats in each group were chosen randomly for evaluation of




where STcontrol and STtest are the average survival time (days) for
the rats administered with normal saline and with test agent,
respectively.
The remaining rats in each group were sacrificed and their
tumors were removed for examination. The longest (a) and the
shortest (b) vertical dimensions of the tumor were measured.
The size (V) and growth rate (GR) of the tumor were calculated
using the following equations [21]:
V ¼ ab2=2;
and
GR ¼ Tumor size after 7 days of treatment
Tumor size before treatment
:
Representative formalin-fixed, paraffin-embedded tissue
blocks from each tumor were analyzed by conventional
hematoxylin-eosin (HE) staining. The degree of necrosis in
each tumor examined was visually graded as follows: −/+, no
necrosis present or slight necrosis in fragmentis; ++, mid-range
necrosis, absence of nuclei from many cells with or without
massive cytoplasmic damage; and +++, severe necrosis, total
loss of cytoplasm of the cancer cells.
Statistical analysis of data was carried out by SPSS program.
Differences were assessed for significance using the one-way
ANOVA or unpaired t-tests as appropriate. The level of
significance was set at α=0.05. Regression analysis was carried
out to determine linear relationship between variables.
3. Results and discussion
3.1. Morphology and drug content of microspheres
The three types of microspheres prepared were compared.
The alginate and PLGA microspheres were prepared by the
formation of primary emulsions while PLGA-alginate micro-
spheres involved multiple emulsions. The latter enabled the
formation of composite microspheres which were specifically
designed to act more effectively as a chemoembolization agent.
Using the emulsification method, all the formulations produced
free-flowing powders. Upon dispersing the powder in water,
relatively discrete and spherical microspheres were observed
under the microscope. Unlike the alginate or PLGA micro-
spheres, the alginate-PLGA composite microspheres (BPAM
and NPAM) possessed numerous spherical inclusions (Fig. 1).
In the formation of the composite microspheres, PLGA droplets
were stable in the alginate solution and gradually solidified to
form micro-spheroid inclusions in the cross-linked alginate
matrix as the solvent was removed. All the batches of
microspheres showed unimodal size distribution (Fig. 2).
NPAM was prepared with different concentrations of sodium
alginate to examine the effect of varying PLGA:alginate ratios.
Majority of the batches of NPAM had particles in the size range
of 30–100 μm. The mean particle size increased linearly with
increasing concentration of sodium alginate employed (Table 1,
r=0.957). As solutions of higher alginate concentrations were
more viscous and harder to disperse, large alginate globules
were formed, resulting in larger microspheres.
The PLGA-alginate microspheres had relatively low con-
tents of norcantharidin (2.5–4.3% w/w). However, they were
mostly higher than those of microspheres prepared using
only alginate (drug content, 2.6% w/w) or PLGA (drug content,
3.9% w/w). The low drug contents could be aptly accounted by
the high aqueous solubility of norcantharidin (9.3 g/100 ml at
20 °C), resulting in considerable drug loss to the aqueous
medium during emulsification and washing. Nevertheless,
norcantharidin is very potent, requiring only small quantities
for therapeutic activity and the final dose can be adjusted by the
quantity of microspheres administered. In this study, NPAM
Fig. 2. Size distribution of alginate, PLGA and PLGA-alginate (1:3)
microspheres.
Fig. 3. Release profiles of microspheres: alginate (○), PLGA-alginate (1:3) (□)
and PLGA (Δ).
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was prepared with constant amounts of PLGA and norcanthar-
idin, but varying amounts of sodium alginate. Results showed
that NPAM prepared with a higher alginate concentration had
higher norcantharidin content. The encapsulation efficiency
increased from 10.8% to 33.0% when alginate concentration
was increased from 1% to 3%. Thus, increasing the alginate
content decreased drug loss during preparation.
The liver is supported by arterioles that branch from the hepatic
artery. It was reported that the diameters of normal arterioles (20–
30 μm) were much smaller than those supplying the Walker 256
carcinoma (25–75 μm) [22]. Hence, injection of microspheres in
the latter size range would lead to their capture in the carcinoma
arterioles but by-pass those that supply the normal tissue.
Microspheres larger than 100 μm are undesirable as they would
be trapped in the primary vessels and cause major obstruction to
the supply of nutrients and oxygen to most part of the organ,
leading to liver failure. Hence, it is important that microspheres of
appropriate size are used. Ideally, the microspheres administered
are of varying sizes to produce more effective embolization [23].
In this study, all the batches of microspheres conformed to the
aforementioned size requirement.
3.2. In vitro drug release
NPAM prepared with an alginate concentration of 3% w/w
(Table 1) was selected for comparison with the alginate mic-
rospheres and PLGAmicrospheres. Drug release from the alginate
microspheres was comparatively very fast, with more than 90%
norcantharidin releasedwithin an hour of the dissolution test. Such
microspheres were unable to provide sufficient sustained drug
release for maintaining a constant drug level. In contrast, drug
release from the PLGA microspheres was extremely slow, with
only about 30% norcantharidin released after 24 h. Most of the
drugwas released from these microspheres during the initial burst
phase. As a result, they were considered not to be able to provide
the effective drug release level. The composite NPAM micro-
spheres showed an intermediate drug release profile. After an
initial rapid release phase (burst effect), a zero order release profile
(r=0.949) was observed. The burst release was even marginally
less than that observed for the PLGA microspheres (Fig. 3). The
moderate release rate of NPAM microspheres would be able to
provide an effective drug level for a much longer period of time
than the alginate microspheres. It was reported that side-effects of
the chemoembolized drug was caused by the burst release effect
of the drug [24]. Hence, burst effect should be kept as small as
possible. The burst effect of a drug in a delivery system is usually
brought about by free drug present on or near to the surface of the
microspheres. Much of this is attributed to the drying process
when solvent migrates from the interior to the surface of the
microsphere, bringing with it the dissolved drug. NPAM showed
markedly less burst effect than alginate microspheres and it was
even lower than that of the slow releasing PLGA microspheres.
Incorporating norcantharidin in PLGA, which was in turn
entrapped as micro-spheroids in the alginate matrix significantly
reduced the burst effect (Table 1). The percent drug released due
to burst effect decreased with higher proportion of alginate in the
composite microspheres. However, the subsequent release rates
were comparable, indicating that drug release was controlled by
the PLGA micro-spheroids entrapped in the alginate matrix. The
sustaining effect attributed to alginate was probably minimal and
alginate actedmore as a porous structuralmatrix producing a solid
dispersion of micro-spheroids of PLGA.
A three-phase degradation mechanism was proposed for
PLGA [25]. In the first phase, random hydrolytic chain scissions
of swollen polymer occurred. The molecular weight of the
polymer decreased significantly, but no appreciable weight loss
and soluble monomers were detected. In the second phase, further
degradation of the polymer to soluble oligomers led to
progressive weight loss. Finally, the oligomers were cleaved to
form monomers. Overall, PLGA is a very stable polymer that
remains intact for months in the biological fluid [12]. In this study,
the dissolution profile of PLGA-alginate microspheres showed a
two-stage release. The burst release of 10.5% drug in the first hour
was attributed to the drug located close to the surface of the
microsphere. This was followed by a markedly slower release
stage that was largely governed by the degradation of PLGA.
3.3. Disintegration time
PLGA microspheres took more than 14 days to disintegrate in
pH7.4 phosphate buffer solution. In contrast, alginatemicrospheres
disintegrated relatively fast, within 2 h. The disintegration time of
Fig. 4. Growth inhibitory effects ofNPAMandBPAMonSMMC-7721 liver cancer
cells. NPAM composed of PLGA:alginate (1:3) with 4.3% w/w norcantharidin.
Fig. 5. Growth inhibitory effects of NPAM on SMMC-7721 liver cancer cells.
NPAM composed of PLGA:alginate (1:3) with 4.3% w/w norcantharidin.
39X. Liu et al. / Journal of Controlled Release 116 (2006) 35–41
PLGA-alginate microspheres was intermediate, about 4 days,
indicating that the addition of PLGA helped to preserve the
integrity of the composite microspheres. It was reported that PLGA
microspheres take several months to break down in the
physiological fluid [12]. Thus, PLGA microspheres were likely
to produce long-term embolization, which might result in the
development of collateral circulation to bypass the occluded vessel.
It was also proposed that the embolization material should break
down within several days to avoid foreign body reactions [26].
With due consideration to the above reports, the composite PLGA-
alginate microspheres would be more suitable than the alginate
microspheres or PLGAmicrospheres as the embolization agent for
animal trials.
3.4. Growth inhibitory effect of NPAM on liver cancer cells
BPAM had minimal growth inhibitory effect on the liver
cancer cells studied, indicating that both alginate and PLGA did
not exhibit cytotoxicity (Fig. 4). Cancer cells exposed to 5 μg/ml
of NPAM for 24 h were however significantly inhibited
(GI=11.6%). The extent of growth inhibition increased fairly
linearly with the concentration of NPAM (r=0.964), indicating
that the inhibitory effect was concentration dependent (Fig. 5).
Similar trend was observed for exposure time of 48 h (r=0.933)
and 72 h (r=0.939). Using linear regression, the slopes of the best
straight lines for exposure time of 24, 48 and 72 h were found to
be 0.30, 0.34 and 0.33 respectively. This showed that the
concentration effect was increased when the exposure time was
increased from 24 to 48 h, but it was minimally affected when the
exposure time was further increased. The concentrations required
to inhibit 50% of the cells (IC50) for exposure time of 24, 48 and
72 h were found to be 110.2, 70.6 and 35.5 μg/ml respectively. At
5 μg/ml of NPAM, there was insignificant difference in growth
inhibitory effect between exposure time of 24 and 48 h (Fig. 5).
However, further increase in exposure time increased the growth
inhibitory effect. Clearly, higher concentrations of NPAM
produced considerable increase in growth inhibitory effects.
The slopes of growth inhibitory effect versus time indicated that
time-related inhibitory effect increased was smaller than that of
NPAM concentration.
3.5. Therapeutic efficacy of NPAM on rats bearing trans-
planted hepatoma
Tumor size of rats administered with normal saline increased
markedly after 7 days (Fig. 6). Of the rats used, 8 out of 9
suffered from diffuse metastasis and 6 of them developed
ascites. Interestingly, the tumor size of rats treated with
norcantharidin solution also increased despite causing a
considerable extent of necrosis (Fig. 7C). The latter was due
to the toxic effect of a high dose of norcantharidin from the
solution. As the effect was not sustaining, the tumor could
propagate and increase in tumor size despite the extent of
necrosis of tumor caused. Similar finding was also observed for
BPAM, indicating that embolization alone was inadequate for
treating liver tumor. Among the test agents, only NPAM was
capable of preventing the growth of the tumor. In addition, 7 of
Table 2
Effects of various treatments on necrosis of tumor
Group n Score
−/+ +/+ +++
1. Normal saline (1.5 ml/kg) 9 8 1 0
2. 0.03% w/v norcantharidin solution (1.5 ml/kg) 7 2 5 0
3. BPAM (10 mg/kg) 8 2 5 1
4. NPAM (10 mg/kg) 9 0 2 7
BPAM and NPAM were composed of PLGA:alginate (1:3).
Table 3
Effects of various treatments on the survival of rats with transplanted hepatoma




1 Normal saline (1.5 ml/kg) 6 13.7±2.2
2 0.03% w/v norcantharidin solution
(1.5 ml/kg)
6 15.8±2.0 15.8
3 BPAM (10 mg/kg) 6 16.5±3.0 20.7
4 NPAM (10 mg/kg) 6 31.0±3.9 126.8
BPAM and NPAM were composed of PLGA:alginate (1:3).
Fig. 6. Tumor response to treatment with various agents. GR is the growth rate of
the tumor treated with the respective agent.
Fig. 7. Histopathological characteristics of tumor (A) extensive infarction and (B)
mid-range infarction after treatment with NPAM; (C) mid-range infarction after
treatment with norcantharidin solution; (D) slight necrosis in fragmentis after
treatment with normal saline.
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the rats treated with NPAM showed necrosis that was
significantly greater than that of other groups (Table 2,
pb0.005). The effect of NPAM on the survival time of rats
with transplanted hepatoma was also determined (Table 3). All
the rats eventually died of carcinomatous and bloody ascites.
Compared with the control group treated with normal saline,
these symptoms were observed much later in the NPAM-treated
test group. The control group was found to have the shortest
survival time of 13.7 days. Both BPAM and norcantharidin
solution increased the survival time to comparable extents
( pN0.05). This showed that embolization played an equally
important role as the drug in the treatment of hepatoma. Among
the test agents, NPAM showed to be the most promising, with
the longest survival time ( pb0.01) and highest survival rate of
126.8%. In terms of survival rate, the NPAMmicrospheres were
at least 6 times more effective than either the use of
norcantharidin solution or BPAM.
4. Conclusion
Composite PLGA-alginate microspheres in the desired size
range were successfully prepared by a double emulsification
method. The size of the microspheres increased with the
concentration of alginate employed. The composite micro-
spheres showed drug release rate that was intermediate between
alginate microspheres and PLGA microspheres. The release
profile was characterized by initial burst effect, followed by
zero order release. The release rate was governed mainly by the
entrapped PLGA microspheroids, with the alginate matrix
having minimal role. Norcantharidin-loaded composite micro-
spheres were markedly more effective than norcantharidin
solution and blank microspheres in preventing tumor growth
and increasing survival time of rats transplanted with hepatoma.
These novel microspheres, which demonstrated synergistic
effect of chemotherapy and embolization, are promising for the
treatment of liver cancer.
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